Musculoskeletal Diseases: Mechanisms and Therapeutic Advances

Abstract

Musculoskeletal diseases encompass a broad spectrum of inflammatory, degenerative, and neoplastic disorders that compromise bone and joint function across the lifespan. Increasing evidence highlights the central role of immune regulation in their pathogenesis, driven by complex interactions among immune, bone, and stromal cells. Inflammatory conditions such as rheumatoid arthritis, ankylosing spondylitis, and dermatomyositis are marked by persistent immune activation and progressive tissue destruction. Degenerative diseases like osteoarthritis, osteoporosis, and intervertebral disc degeneration involve immune senescence, dysregulated tissue remodeling, and inflammation-driven structural damage. Bone and soft tissue tumors—including osteosarcoma, chondrosarcoma, Ewing sarcoma, and soft tissue sarcoma—develop within immunosuppressive niches that hinder antitumor immunity. Notably, these immune environments are not strictly dichotomous but exhibit dynamic, context-dependent states of immune stimulation and suppression. This review delineates both shared and disease-specific immune mechanisms, spanning cytokine networks, signaling pathways, and cellular interactions. It further discusses current and emerging therapeutic strategies, including cytokine modulators, bone-regulatory agents, immune checkpoint inhibitors, and cell-based therapies. Despite recent advances, key challenges persist in translating immunological insights into durable, disease-modifying treatments. By bridging mechanisms across inflammation, degeneration, and malignancy, this review provides an integrated framework for understanding immune contributions to musculoskeletal diseases and identifies promising directions for precision immunotherapy.

Keywords

bone and soft tissue tumors / immune modulation / inflammation / musculoskeletal diseases / precision immunotherapy

References

[1] C. Mancino, M. Franke, A. Greco, et al., “RNA Therapies for Musculoskeletal Conditions,” Journal of Control Release 377 (2025): 756–766.

[2] D. Goltzman, “Discoveries, Drugs and Skeletal Disorders,” Nature Reviews Drug Discovery 1, no. 10 (2002): 784–796.

[3] M. Hayashi, T. Nakashima, M. Taniguchi, T. Kodama, A. Kumanogoh, and H. Takayanagi, “Osteoprotection by Semaphorin 3A,” Nature 485, no. 7396 (2012): 69–74.

[4] J. Sieper and D. Poddubnyy, “Axial Spondyloarthritis,” Lancet 390, no. 10089 (2017): 73–84.

[5] J. S. Smolen, D. Aletaha, and I. B. McInnes, “Rheumatoid Arthritis,” Lancet 388, no. 10055 (2016): 2023–2038.

[6] B. Yu and C. Y. Wang, “Osteoporosis and Periodontal Diseases—An Update on Their Association and Mechanistic Links,” Periodontology 2000 89, no. 1 (2022): 99–113.

[7] K. Okamoto, T. Nakashima, M. Shinohara, et al., “Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems,” Physiological Reviews 97, no. 4 (2017): 1295–1349.

[8] H. Takayanagi, “Osteoimmunology: Shared Mechanisms and Crosstalk Between the Immune and Bone Systems,” Nature Reviews Immunology 7, no. 4 (2007): 292–304.

[9] H. Takayanagi, K. Ogasawara, S. Hida, et al., “T-cell-mediated Regulation of Osteoclastogenesis by Signalling Cross-talk Between RANKL and IFN-gamma,” Nature 408, no. 6812 (2000): 600–605.

[10] N. L. Rosenberg, S. P. Ringel, and B. L. Kotzin, “Experimental Autoimmune Myositis in SJL/J Mice,” Clinical and Experimental Immunology 68, no. 1 (1987): 117–129.

[11] N. L. Millar, K. G. Silbernagel, K. Thorborg, et al., “Tendinopathy,” Nature Reviews Disease Primers 7, no. 1 (2021): 1.

[12] M. N. Weitzmann and I. Ofotokun, “Physiological and Pathophysiological Bone Turnover—role of the Immune System,” Nature Reviews Endocrinology 12, no. 9 (2016): 518–532.

[13] S. L. Teitelbaum and F. P. Ross, “Genetic Regulation of Osteoclast Development and Function,” Nature Reviews Genetics 4, no. 8 (2003): 638–649.

[14] Y. Xiong, B. B. Mi, Z. Lin, et al., “The Role of the Immune Microenvironment in Bone, Cartilage, and Soft Tissue Regeneration: From Mechanism to Therapeutic Opportunity,” Military Medical Research 9, no. 1 (2022): 65.

[15] K. Horas, C. Menale, and A. Maurizi, “Editorial: The Bone/Bone Marrow Microenvironment: A Hub for Immune Regulation of the Tumor Cells Fate,” Frontiers in Immunology 13 (2022): 1019489.

[16] A. G. Robling and L. F. Bonewald, “The Osteocyte: New Insights,” Annual Review of Physiology 82 (2020): 485–506.

[17] Q. Chen, P. Shou, C. Zheng, et al., “Fate Decision of Mesenchymal Stem Cells: Adipocytes or Osteoblasts?,” Cell Death and Differentiation 23, no. 7 (2016): 1128–1139.

[18] M. Ponzetti and N. Rucci, “Osteoblast Differentiation and Signaling: Established Concepts and Emerging Topics,” International Journal of Molecular Sciences 22, no. 13 (2021): 6651.

[19] I. Takada, A. P. Kouzmenko, and S. Kato, “Wnt and PPARgamma Signaling in Osteoblastogenesis and Adipogenesis,” Nature Reviews Rheumatology 5, no. 8 (2009): 442–447.

[20] N. Udagawa, M. Koide, M. Nakamura, et al., “Osteoclast Differentiation by RANKL and OPG Signaling Pathways,” Journal of Bone and Mineral Metabolism 39, no. 1 (2021): 19–26.

[21] L. de la Rica, A. Garcia-Gomez, N. R. Comet, et al., “NF-kappaB-direct Activation of microRNAs With Repressive Effects on Monocyte-specific Genes Is Critical for Osteoclast Differentiation,” Genome Biology 16, no. 1 (2015): 2.

[22] R. Leung, K. Cuddy, Y. Wang, J. Rommens, and M. Glogauer, “Sbds Is Required for Rac2-mediated Monocyte Migration and Signaling Downstream of RANK During Osteoclastogenesis,” Blood 117, no. 6 (2011): 2044–2053.

[23] R. J. Miron, M. Bohner, Y. Zhang, and D. D. Bosshardt, “Osteoinduction and Osteoimmunology: Emerging Concepts,” Periodontology 2000 94, no. 1 (2024): 9–26.

[24] Y. Li, G. Toraldo, A. Li, et al., “B Cells and T Cells Are Critical for the Preservation of Bone Homeostasis and Attainment of Peak Bone Mass in Vivo,” Blood 109, no. 9 (2007): 3839–3848.

[25] A. Bozec, M. M. Zaiss, R. Kagwiria, et al., “T Cell Costimulation Molecules CD80/86 Inhibit Osteoclast Differentiation by Inducing the IDO/Tryptophan Pathway,” Science Translational Medicine 6, no. 235 (2014): 235ra60.

[26] L. W. Lai, K. C. Yong, and Y. H. Lien, “Pharmacologic Recruitment of Regulatory T Cells as a Therapy for Ischemic Acute Kidney Injury,” Kidney International 81, no. 10 (2012): 983–992.

[27] L. Goschl, C. Scheinecker, and M. Bonelli, “Treg Cells in Autoimmunity: From Identification to Treg-based Therapies,” Seminars in Immunopathology 41, no. 3 (2019): 301–314.

[28] M. Arizon, I. Nudel, H. Segev, et al., “Langerhans Cells Down-regulate Inflammation-driven Alveolar Bone Loss,” Proceedings of the National Academy of Sciences of the United States of America 109, no. 18 (2012): 7043–7048.

[29] A. Bozec and M. M. Zaiss, “T Regulatory Cells in Bone Remodelling,” Current Osteoporosis Reports 15, no. 3 (2017): 121–125.

[30] M. Noack and P. Miossec, “Th17 and Regulatory T Cell Balance in Autoimmune and Inflammatory Diseases,” Autoimmunity Reviews 13, no. 6 (2014): 668–677.

[31] Z. S. Buchwald, J. R. Kiesel, R. DiPaolo, M. S. Pagadala, and R. Aurora, “Osteoclast Activated FoxP3+ CD8+ T-cells Suppress Bone Resorption in Vitro,” PLoS ONE 7, no. 6 (2012): e38199.

[32] L. Jia, Y. Tu, X. Jia, et al., “Probiotics Ameliorate Alveolar Bone Loss by Regulating Gut Microbiota,” Cell Proliferation 54, no. 7 (2021): e13075.

[33] L. Gonzalez-Osuna, A. Sierra-Cristancho, C. Rojas, et al., “Premature Senescence of T-cells Favors Bone Loss during Osteolytic Diseases. A New Concern in the Osteoimmunology Arena,” Aging and Disease 12, no. 5 (2021): 1150–1161.

[34] M. K. Chang, L. J. Raggatt, K. A. Alexander, et al., “Osteal Tissue Macrophages Are Intercalated throughout human and Mouse Bone Lining Tissues and Regulate Osteoblast Function in Vitro and in Vivo,” Journal of Immunology 181, no. 2 (2008): 1232–1244.

[35] C. J. Li, Y. Xiao, Y. C. Sun, et al., “Senescent Immune Cells Release Grancalcin to Promote Skeletal Aging,” Cell Metabolism 33, no. 10 (2021): 1957–1973. e6.

[36] C. Schlundt, H. Fischer, C. H. Bucher, C. Rendenbach, G. N. Duda, and K. Schmidt-Bleek, “The Multifaceted Roles of Macrophages in Bone Regeneration: A Story of Polarization, Activation and Time,” Acta Biomaterialia 133 (2021): 46–57.

[37] I. G. Winkler, N. A. Sims, A. R. Pettit, et al., “Bone Marrow Macrophages Maintain Hematopoietic Stem Cell (HSC) Niches and Their Depletion Mobilizes HSCs,” Blood 116, no. 23 (2010): 4815–4828.

[38] K. L. Spiller, R. R. Anfang, K. J. Spiller, et al., “The Role of Macrophage Phenotype in Vascularization of Tissue Engineering Scaffolds,” Biomaterials 35, no. 15 (2014): 4477–4488.

[39] X. Cui, L. Xu, Y. Shan, J. Li, J. Ji, and E. Wang, “Piezocatalytically-induced Controllable Mineralization Scaffold With Bone-Like Microenvironment to Achieve Endogenous Bone Regeneration,” Science Bulletin (Beijing) 69, no. 12 (2024): 1895–1908.

[40] X. Lin, S. Patil, Y. G. Gao, and A. Qian, “The Bone Extracellular Matrix in Bone Formation and Regeneration,” Frontiers in Pharmacology 11 (2020): 757.

[41] M. D. Shoulders and R. T. Raines, “Collagen Structure and Stability,” Annual Review of Biochemistry 78 (2009): 929–958.

[42] M. Murshed, “Mechanism of Bone Mineralization,” Cold Spring Harbor Perspectives in Medicine 8, no. 12 (2018): a031229.

[43] H. Fonseca, D. Moreira-Goncalves, H. J. Coriolano, and J. A. Duarte, “Bone Quality: The Determinants of Bone Strength and Fragility,” Sports Medicine (Auckland, NZ) 44, no. 1 (2014): 37–53.

[44] A. Persson, M. Nikpour, E. Vorontsov, J. Nilsson, and G. Larson, “Domain Mapping of Chondroitin/Dermatan Sulfate Glycosaminoglycans Enables Structural Characterization of Proteoglycans,” Molecular & Cellular Proteomics 20 (2021): 100074.

[45] P. G. Scott, P. A. McEwan, C. M. Dodd, E. M. Bergmann, P. N. Bishop, and J. Bella, “Crystal Structure of the Dimeric Protein Core of Decorin, the Archetypal Small Leucine-rich Repeat Proteoglycan,” Proceedings of the National Academy of Sciences of the United States of America 101, no. 44 (2004): 15633–15638.

[46] A. Sorvina, M. Antoniou, Z. Esmaeili, and M. Kochetkova, “Unusual Suspects: Bone and Cartilage ECM Proteins as Carcinoma Facilitators,” Cancers (Basel) 15, no. 3 (2023): 791.

[47] M. B. Chavez, M. H. Tan, T. N. Kolli, et al., “Bone Sialoprotein Is Critical for Alveolar Bone Healing in Mice,” Journal of Dental Research 102, no. 2 (2023): 187–196.

[48] F. F. Mohamed, B. Hoac, A. Phanrungsuwan, et al., “Contributions of Increased Osteopontin and Hypophosphatemia to Dentoalveolar Defects in Osteomalacic Hyp Mice,” Bone 176 (2023): 116886.

[49] B. Kirk, G. Lombardi, and G. Duque, “Bone and Muscle Crosstalk in Ageing and Disease,” Nature Reviews Endocrinology 21, no. 6 (2025): 375–390.

[50] Z. Zhang, S. Lin, W. Luo, et al., “Sox6 Differentially Regulates Inherited Myogenic Abilities and Muscle Fiber Types of Satellite Cells Derived From Fast- and Slow-Type Muscles,” International Journal of Molecular Sciences 23, no. 19 (2022): 11327.

[51] C. Rodriguez, F. Timoteo-Ferreira, G. Minchiotti, S. Brunelli, and O. Guardiola, “Cellular Interactions and Microenvironment Dynamics in Skeletal Muscle Regeneration and Disease,” Frontiers in Cell and Developmental Biology 12 (2024): 1385399.

[52] M. R. Hicks and A. D. Pyle, “The Emergence of the Stem Cell Niche,” Trends in Cell Biology 33, no. 2 (2023): 112–123.

[53] C. Sciorati, E. Rigamonti, A. A. Manfredi, and P. Rovere-Querini, “Cell Death, Clearance and Immunity in the Skeletal Muscle,” Cell Death and Differentiation 23, no. 6 (2016): 927–937.

[54] B. N. VanderVeen, E. A. Murphy, and J. A. Carson, “The Impact of Immune Cells on the Skeletal Muscle Microenvironment during Cancer Cachexia,” Frontiers in Physiology 11 (2020): 1037.

[55] Z. You, X. Huang, Y. Xiang, J. Dai, J. Jiang, and J. Xu, “Molecular Feature of Neutrophils in Immune Microenvironment of Muscle Atrophy,” Journal of Cellular and Molecular Medicine 26, no. 17 (2022): 4658–4665.

[56] M. Becker, S. S. Joseph, F. Garcia-Carrizo, et al., “Regulatory T Cells Require IL6 Receptor Alpha Signaling to Control Skeletal Muscle Function and Regeneration,” Cell Metabolism 35, no. 10 (2023): 1736–1751. e7.

[57] R. P. Wohlgemuth, S. Sriram, K. E. Henricson, D. T. Dinh, S. E. Brashear, and L. R. Smith, “Strain-dependent Dynamic Re-alignment of Collagen Fibers in Skeletal Muscle Extracellular Matrix,” Acta Biomaterialia 187 (2024): 227–241.

[58] R. P. Wohlgemuth, S. E. Brashear, and L. R. Smith, “Alignment, Cross Linking, and Beyond: A Collagen Architect's Guide to the Skeletal Muscle Extracellular Matrix,” American Journal of Physiology. Cell Physiology 325, no. 4 (2023): C1017–C1030.

[59] X. Ge, Y. Jin, J. He, Z. Jia, Y. Liu, and Y. Xu, “Extracellular Matrix in Skeletal Muscle Injury and Atrophy: Mechanisms and Therapeutic Implications,” Journal of Orthopaedic Translation 52 (2025): 404–418.

[60] P. Mohassel, H. Hearn, J. Rooney, et al., “Collagen Type VI Regulates TGF-beta Bioavailability in Skeletal Muscle in Mice,” Journal of Clinical Investigation 135, no. 9 (2025): e173354.

[61] S. S. Rayagiri, D. Ranaldi, A. Raven, et al., “Basal Lamina Remodeling at the Skeletal Muscle Stem Cell Niche Mediates Stem Cell Self-renewal,” Nature Communications 9, no. 1 (2018): 1075.

[62] M. Gomez-Florit, C. J. Labrador-Rached, R. M. A. Domingues, and M. E. Gomes, “The Tendon Microenvironment: Engineered in Vitro Models to Study Cellular Crosstalk,” Advanced Drug Delivery Reviews 185 (2022): 114299.

[63] A. Dede Eren, S. Vermeulen, T. C. Schmitz, J. Foolen, and J. de Boer, “The Loop of Phenotype: Dynamic Reciprocity Links Tenocyte Morphology to Tendon Tissue Homeostasis,” Acta Biomaterialia 163 (2023): 275–286.

[64] A. Goto, S. Komura, K. Kato, et al., “PI3K-Akt Signalling Regulates Scx-lineage Tenocytes and Tppp3-lineage Paratenon Sheath Cells in Neonatal Tendon Regeneration,” Nature Communications 16, no. 1 (2025): 3734.

[65] S. Chen, Y. Lin, H. Yang, et al., “A CD26(+) Tendon Stem Progenitor Cell Population Contributes to Tendon Repair and Heterotopic Ossification,” Nature Communications 16, no. 1 (2025): 749.

[66] V. Russo, M. El Khatib, G. Prencipe, et al., “Tendon Immune Regeneration: Insights on the Synergetic Role of Stem and Immune Cells During Tendon Regeneration,” Cells 11, no. 3 (2022): 434.

[67] C. A. Bautista, A. Srikumar, E. D. Tichy, et al., “CD206+ tendon Resident Macrophages and Their Potential Crosstalk With Fibroblasts and the ECM During tendon Growth and Maturation,” Frontiers in Physiology 14 (2023): 1122348.

[68] C. Lehner, G. Spitzer, R. Gehwolf, et al., “Tenophages: A Novel Macrophage-Like Tendon Cell Population Expressing CX3CL1 and CX3CR1,” Disease Models & Mechanisms 12, no. 12 (2019): dmm041384.

[69] M. A. Alim, M. Peterson, and G. Pejler, “Do Mast Cells Have a Role in Tendon Healing and Inflammation?,” Cells 9, no. 5 (2020): 1134.

[70] R. Mousavizadeh, C. M. Waugh, R. G. McCormack, B. E. Cairns, and A. Scott, “MRGPRX2-mediated Mast Cell Activation by Substance P From Overloaded human Tenocytes Induces Inflammatory and Degenerative Responses in Tendons,” Scientific Reports 14, no. 1 (2024): 13540.

[71] A. C. Noah, T. M. Li, L. M. Martinez, et al., “Adaptive and Innate Immune Cell Responses in Tendons and Lymph Nodes After Tendon Injury and Repair,” Journal of Applied Physiology (1985) 128, no. 3 (2020): 473–482.

[72] K. T. Tam and K. Baar, “Using Load to Improve Tendon/Ligament Tissue Engineering and Develop Novel Treatments for Tendinopathy,” Matrix Biology 135 (2025): 39–54.

[73] M. Stanczak, B. Kacprzak, and P. Gawda, “Tendon Cell Biology: Effect of Mechanical Loading,” Cellular Physiology and Biochemistry 58, no. 6 (2024): 677–701.

[74] H. Wolfenson, B. Yang, and M. P. Sheetz, “Steps in Mechanotransduction Pathways That Control Cell Morphology,” Annual Review of Physiology 81 (2019): 585–605.

[75] M. Li, T. Deng, Q. Chen, et al., “A Versatile Platform Based on Matrix Metalloproteinase-sensitive Peptides for Novel Diagnostic and Therapeutic Strategies in Arthritis,” Bioactive Materials 47 (2025): 100–120.

[76] P. Brown, A. G. Pratt, and K. L. Hyrich, “Therapeutic Advances in Rheumatoid Arthritis,” Bmj 384 (2024): e070856.

[77] M. Kurowska-Stolarska and S. Alivernini, “Synovial Tissue Macrophages in Joint Homeostasis, Rheumatoid Arthritis and Disease Remission,” Nature Reviews Rheumatology 18, no. 7 (2022): 384–397.

[78] J. S. Smolen, D. Aletaha, M. Koeller, M. H. Weisman, and P. Emery, “New Therapies for Treatment of Rheumatoid Arthritis,” Lancet 370, no. 9602 (2007): 1861–1874.

[79] I. A. Udalova, A. Mantovani, and M. Feldmann, “Macrophage Heterogeneity in the Context of Rheumatoid Arthritis,” Nature Reviews Rheumatology 12, no. 8 (2016): 472–485.

[80] D. Kuo, J. Ding, I. S. Cohn, et al., “HBEGF(+) Macrophages in Rheumatoid Arthritis Induce Fibroblast Invasiveness,” Science Translational Medicine 11, no. 491 (2019): eaau8587.

[81] X. Zhang, Z. Zhang, Y. Zhao, L. Jin, Y. Tai, and Y. Tang, “Sodium Chloride Promotes Macrophage Pyroptosis and Aggravates Rheumatoid Arthritis by Activating SGK1 Through GABA Receptors Slc6a12,” International Journal of Biological Sciences 20, no. 8 (2024): 2922–2942.

[82] K. Ley, H. M. Hoffman, P. Kubes, et al., “Neutrophils: New Insights and Open Questions,” Science Immunology 3, no. 30 (2018): eaat4579.

[83] V. Papayannopoulos, “Neutrophil Extracellular Traps in Immunity and Disease,” Nature Reviews Immunology 18, no. 2 (2018): 134–147.

[84] L. J. O'Neil and M. J. Kaplan, “Neutrophils in Rheumatoid Arthritis: Breaking Immune Tolerance and Fueling Disease,” Trends in Molecular Medicine 25, no. 3 (2019): 215–227.

[85] F. Wu, J. Gao, J. Kang, et al., “B Cells in Rheumatoid Arthritis: Pathogenic Mechanisms and Treatment Prospects,” Frontiers in Immunology 12 (2021): 750753.

[86] S. K. O'Neill, M. J. Shlomchik, T. T. Glant, Y. Cao, P. D. Doodes, and A. Finnegan, “Antigen-specific B Cells Are Required as APCs and Autoantibody-producing Cells for Induction of Severe Autoimmune Arthritis,” Journal of Immunology 174, no. 6 (2005): 3781–3788.

[87] W. Sun, N. Meednu, A. Rosenberg, et al., “B Cells Inhibit Bone Formation in Rheumatoid Arthritis by Suppressing Osteoblast Differentiation,” Nature Communications 9, no. 1 (2018): 5127.

[88] L. Laurent, F. Anquetil, C. Clavel, et al., “IgM Rheumatoid Factor Amplifies the Inflammatory Response of Macrophages Induced by the Rheumatoid Arthritis-specific Immune Complexes Containing Anticitrullinated Protein Antibodies,” Annals of the Rheumatic Diseases 74, no. 7 (2015): 1425–1431.

[89] Y. Y. Kong, U. Feige, I. Sarosi, et al., “Activated T Cells Regulate Bone Loss and Joint Destruction in Adjuvant Arthritis Through Osteoprotegerin Ligand,” Nature 402, no. 6759 (1999): 304–309.

[90] H. Ye, D. Fu, X. Fang, Y. Xie, X. Zheng, and W. Fan, “Casein Kinase II Exacerbates Rheumatoid Arthritis via Promoting Th1 and Th17 Cell Inflammatory Responses,” Expert Opinion on Therapeutic Targets 25, no. 11 (2021): 1017–1024.

[91] N. Komatsu and H. Takayanagi, “Mechanisms of Joint Destruction in Rheumatoid Arthritis—immune Cell-fibroblast-bone Interactions,” Nature Reviews Rheumatology 18, no. 7 (2022): 415–429.

[92] A. T. Shaw, Y. Maeda, and E. M. Gravallese, “IL-17A Deficiency Promotes Periosteal Bone Formation in a Model of Inflammatory Arthritis,” Arthritis Research & Therapy 18, no. 1 (2016): 104.

[93] T. Ono, K. Okamoto, T. Nakashima, et al., “IL-17-producing Gammadelta T Cells Enhance Bone Regeneration,” Nature Communications 7 (2016): 10928.

[94] B. Li, R. Su, Q. Guo, et al., “Differential Immunological Profiles in Seronegative versus Seropositive Rheumatoid Arthritis: Th17/Treg Dysregulation and IL-4,” Frontiers in Immunology 15 (2024): 1447213.

[95] J. Iske, Y. Cao, M. J. Roesel, Z. Shen, and Y. Nian, “Metabolic Reprogramming of Myeloid-derived Suppressor Cells in the Context of Organ Transplantation,” Cytotherapy 25, no. 8 (2023): 789–797.

[96] Q. Jiang, J. Duan, L. V. Kaer, and G. Yang, “The Role of Myeloid-Derived Suppressor Cells in Multiple Sclerosis and Its Animal Model,” Aging and Disease 15, no. 3 (2023): 1329–1343.

[97] M. Y. Wu, C. J. Li, G. T. Yiang, et al., “Molecular Regulation of Bone Metastasis Pathogenesis,” Cellular Physiology and Biochemistry 46, no. 4 (2018): 1423–1438.

[98] A. Glover, Z. Zhang, and C. Shannon-Lowe, “Deciphering the Roles of Myeloid Derived Suppressor Cells in Viral Oncogenesis,” Frontiers in Immunology 14 (2023): 1161848.

[99] E. Y. So, C. Sun, K. Q. Wu, P. M. Dubielecka, A. M. Reginato, and O. D. Liang, “Inhibition of Lipid Phosphatase SHIP1 Expands Myeloid-derived Suppressor Cells and Attenuates Rheumatoid Arthritis in Mice,” American Journal of Physiology. Cell Physiology 321, no. 3 (2021): C569–C584.

[100] M. Xue, H. Lin, H. P. H. Liang, et al., “Deficiency of Protease-activated Receptor (PAR) 1 and PAR2 Exacerbates Collagen-induced Arthritis in Mice via Differing Mechanisms,” Rheumatology 60, no. 6 (2021): 2990–3003.

[101] J. F. Charles, L. Y. Hsu, E. C. Niemi, A. Weiss, A. O. Aliprantis, and M. C. Nakamura, “Inflammatory Arthritis Increases Mouse Osteoclast Precursors With Myeloid Suppressor Function,” Journal of Clinical Investigation 122, no. 12 (2012): 4592–4605.

[102] M. Li, Z. Tang, R. Shu, et al., “Polymorphonuclear Myeloid-derived Suppressor Cells Play a Proinflammatory Role via TNF-alpha(+) B Cells Through BAFF/BTK/NF-kappaB Signalling Pathway in the Pathogenesis of Collagen-induced Arthritis Mice,” Immunology 170, no. 2 (2023): 286–300.

[103] L. Liu, D. Deng, C. Li, et al., “The Combination of Modified Acupuncture Needle and Melittin Hydrogel as a Novel Therapeutic Approach for Rheumatoid Arthritis Treatment,” Journal of Nanobiotechnology 22, no. 1 (2024): 432.

[104] P. Shen, Y. Jiao, L. Miao, J. H. Chen, and A. A. Momtazi-Borojeni, “Immunomodulatory Effects of berberine on the Inflamed Joint Reveal New Therapeutic Targets for Rheumatoid Arthritis Management,” Journal of Cellular and Molecular Medicine 24, no. 21 (2020): 12234–12245.

[105] V. Lamontain, T. Schmid, D. Weber-Steffens, et al., “Stimulation of TNF Receptor Type 2 Expands Regulatory T Cells and Ameliorates Established Collagen-induced Arthritis in Mice,” Cellular & Molecular Immunology 16, no. 1 (2019): 65–74.

[106] K. F. Baker, D. McDonald, G. Hulme, et al., “Single-cell Insights Into Immune Dysregulation in Rheumatoid Arthritis Flare versus Drug-free Remission,” Nature Communications 15, no. 1 (2024): 1063.

[107] S. Yan, K. Kotschenreuther, S. Deng, and D. M. Kofler, “Regulatory T Cells in Rheumatoid Arthritis: Functions, Development, Regulation, and Therapeutic Potential,” Cellular and Molecular Life Sciences 79, no. 10 (2022): 533.

[108] H. Sun, W. Gao, W. Pan, et al., “Tim3(+) Foxp3 (+) Treg Cells Are Potent Inhibitors of Effector T Cells and Are Suppressed in Rheumatoid Arthritis,” Inflammation 40, no. 4 (2017): 1342–1350.

[109] T. S. Sumida, N. T. Cheru, and D. A. Hafler, “The Regulation and Differentiation of Regulatory T Cells and Their Dysfunction in Autoimmune Diseases,” Nature Reviews Immunology 24, no. 7 (2024): 503–517.

[110] K. Hattori, S. Tanaka, D. Hashiba, et al., “Synovial Regulatory T Cells Expressing ST2 Deteriorate Joint Inflammation Through the Suppression of Immunoregulatory Eosinophils,” Journal of Autoimmunity 149 (2024): 103333.

[111] M. E. Mickael, I. Bienkowska, and M. Sacharczuk, “An Update on the Evolutionary History of Bregs,” Genes (Basel) 13, no. 5 (2022): 890.

[112] D. Catalan, M. A. Mansilla, A. Ferrier, et al., “Immunosuppressive Mechanisms of Regulatory B Cells,” Frontiers in Immunology 12 (2021): 611795.

[113] E. C. Rosser and C. Mauri, “Regulatory B Cells: Origin, Phenotype, and Function,” Immunity 42, no. 4 (2015): 607–612.

[114] Z. Banko, J. Pozsgay, T. Gati, B. Rojkovich, I. Ujfalussy, and G. Sarmay, “Regulatory B Cells in Rheumatoid Arthritis: Alterations in Patients Receiving Anti-TNF Therapy,” Clinical Immunology 184 (2017): 63–69.

[115] Z. Banko, J. Pozsgay, D. Szili, et al., “Induction and Differentiation of IL-10-Producing Regulatory B Cells From Healthy Blood Donors and Rheumatoid Arthritis Patients,” Journal of Immunology 198, no. 4 (2017): 1512–1520.

[116] D. Cui, L. Zhang, J. Chen, et al., “Changes in Regulatory B Cells and Their Relationship With Rheumatoid Arthritis Disease Activity,” Clinical and Experimental Medicine 15, no. 3 (2015): 285–292.

[117] L. Xu, X. Liu, H. Liu, et al., “Impairment of Granzyme B-Producing Regulatory B Cells Correlates With Exacerbated Rheumatoid Arthritis,” Frontiers in Immunology 8 (2017): 768.

[118] E. R. Zacca, L. I. Onofrio, C. D. V. Acosta, et al., “PD-L1(+) Regulatory B Cells Are Significantly Decreased in Rheumatoid Arthritis Patients and Increase after Successful Treatment,” Frontiers in Immunology 9 (2018): 2241.

[119] M. G. Garimella, S. Kour, V. Piprode, et al., “Adipose-Derived Mesenchymal Stem Cells Prevent Systemic Bone Loss in Collagen-Induced Arthritis,” Journal of Immunology 195, no. 11 (2015): 5136–5148.

[120] Q. Zhao and L. K. Jung, “Frequency of CD19(+)CD24(hi)CD38(hi) Regulatory B Cells Is Decreased in Peripheral Blood and Synovial Fluid of Patients With Juvenile Idiopathic Arthritis: A Preliminary Study,” Pediatric Rheumatology Online Journal 16, no. 1 (2018): 44.

[121] P. Fortea-Gordo, A. Villalba, L. Nuno, et al., “Circulating CD19+CD24hiCD38hi Regulatory B Cells as Biomarkers of Response to Methotrexate in Early Rheumatoid Arthritis,” Rheumatology 59, no. 10 (2020): 3081–3091.

[122] J. Kim, H. J. Lee, I. S. Yoo, S. W. Kang, and J. H. Lee, “Regulatory B Cells Are Inversely Associated With Disease Activity in Rheumatoid Arthritis,” Yonsei Medical Journal 55, no. 5 (2014): 1354–1358.

[123] L. Luo, Q. Liu, S. Peng, et al., “The Number of Regulatory B Cells Is Increased in Mice With Collagen-induced Arthritis,” Open Life Sciences 14 (2019): 12–18.

[124] M. K. Park, Y. O. Jung, S. Y. Lee, et al., “Amelioration of Autoimmune Arthritis by Adoptive Transfer of Foxp3-expressing Regulatory B Cells Is Associated With the Treg/Th17 Cell Balance,” Journal of Translational Medicine 14, no. 1 (2016): 191.

[125] D. Mauro, R. Thomas, G. Guggino, R. Lories, M. A. Brown, and F. Ciccia, “Ankylosing Spondylitis: An Autoimmune or Autoinflammatory Disease?,” Nature Reviews Rheumatology 17, no. 7 (2021): 387–404.

[126] W. Zhu, X. He, K. Cheng, et al., “Ankylosing Spondylitis: Etiology, Pathogenesis, and Treatments,” Bone Research 7 (2019): 22.

[127] Y. Xiong, M. Cai, Y. Xu, et al., “Joint Together: The Etiology and Pathogenesis of Ankylosing Spondylitis,” Frontiers in Immunology 13 (2022): 996103.

[128] M. P. Crawford, S. Sinha, P. S. Renavikar, N. Borcherding, and N. J. Karandikar, “CD4 T Cell-intrinsic Role for the T Helper 17 Signature Cytokine IL-17: Effector Resistance to Immune Suppression,” Proceedings of the National Academy of Sciences of the United States of America 117, no. 32 (2020): 19408–19414.

[129] I. Kryczek, E. Zhao, Y. Liu, et al., “Human TH17 Cells Are Long-lived Effector Memory Cells,” Science Translational Medicine 3, no. 104 (2011): 104ra0.

[130] F. M. Milanez, C. G. Saad, V. T. Viana, et al., “IL-23/Th17 Axis Is Not Influenced by TNF-blocking Agents in Ankylosing Spondylitis Patients,” Arthritis Research & Therapy 18 (2016): 52.

[131] M. Faham, V. Carlton, M. Moorhead, et al., “Discovery of T Cell Receptor Beta Motifs Specific to HLA-B27-Positive Ankylosing Spondylitis by Deep Repertoire Sequence Analysis,” Arthritis & Rheumatology 69, no. 4 (2017): 774–784.

[132] A. L. Hanson, H. J. Nel, L. Bradbury, J. Phipps, R. Thomas, and K. A. Le Cao, “Altered Repertoire Diversity and Disease-Associated Clonal Expansions Revealed by T Cell Receptor Immunosequencing in Ankylosing Spondylitis Patients,” Arthritis & Rheumatology 72, no. 8 (2020): 1289–1302.

[133] M. Zheng, X. Zhang, Y. Zhou, et al., “TCR Repertoire and CDR3 Motif Analyses Depict the Role of Alphabeta T Cells in Ankylosing Spondylitis,” EBioMedicine 47 (2019): 414–426.

[134] E. May, M. L. Dorris, N. Satumtira, et al., “CD8 alpha Beta T Cells Are Not Essential to the Pathogenesis of Arthritis or Colitis in HLA-B27 Transgenic Rats,” Journal of Immunology 170, no. 2 (2003): 1099–1105.

[135] J. D. Taurog, M. L. Dorris, N. Satumtira, et al., “Spondylarthritis in HLA-B27/human beta2-microglobulin-transgenic Rats Is Not Prevented by Lack of CD8,” Arthritis and Rheumatism 60, no. 7 (2009): 1977–1984.

[136] O. V. Britanova, K. R. Lupyr, D. B. Staroverov, et al., “Targeted Depletion of TRBV9(+) T Cells as Immunotherapy in a Patient With Ankylosing Spondylitis,” Nature Medicine 29, no. 11 (2023): 2731–2736.

[137] H. Appel, R. Maier, P. Wu, et al., “Analysis of IL-17(+) Cells in Facet Joints of Patients With Spondyloarthritis Suggests That the Innate Immune Pathway Might be of Greater Relevance Than the Th17-mediated Adaptive Immune Response,” Arthritis Research & Therapy 13, no. 3 (2011): R95.

[138] N. Tamassia, F. Arruda-Silva, F. Calzetti, et al., “A Reappraisal on the Potential Ability of Human Neutrophils to Express and Produce IL-17 Family Members in Vitro: Failure to Reproducibly Detect It,” Frontiers in Immunology 9 (2018): 795.

[139] H. L. Rosenzweig, E. E. Vance, K. Asare-Konadu, et al., “Card9/neutrophil Signalling Axis Promotes IL-17A-mediated Ankylosing Spondylitis,” Annals of the Rheumatic Diseases 83, no. 2 (2024): 214–222.

[140] C. Bridgewood, A. Watad, T. Russell, et al., “Identification of Myeloid Cells in the human Enthesis as the Main Source of Local IL-23 Production,” Annals of the Rheumatic Diseases 78, no. 7 (2019): 929–933.

[141] F. Ciccia, G. Guggino, M. Zeng, et al., “Proinflammatory CX3CR1+CD59+Tumor Necrosis Factor-Like Molecule 1A+Interleukin-23+ Monocytes Are Expanded in Patients with Ankylosing Spondylitis and Modulate Innate Lymphoid Cell 3 Immune Functions,” Arthritis & Rheumatology 70, no. 12 (2018): 2003–2013.

[142] V. Ranganathan, F. Ciccia, F. Zeng, et al., “Macrophage Migration Inhibitory Factor Induces Inflammation and Predicts Spinal Progression in Ankylosing Spondylitis,” Arthritis & Rheumatology 69, no. 9 (2017): 1796–1806.

[143] M. Bollow, T. Fischer, H. Reisshauer, et al., “Quantitative Analyses of Sacroiliac Biopsies in Spondyloarthropathies: T Cells and Macrophages Predominate in Early and Active Sacroiliitis- cellularity Correlates With the Degree of Enhancement Detected by Magnetic Resonance Imaging,” Annals of the Rheumatic Diseases 59, no. 2 (2000): 135–140.

[144] D. McGonagle, H. Marzo-Ortega, P. O'Connor, W. Gibbon, P. Hawkey, and K. Henshaw, “Histological Assessment of the Early Enthesitis Lesion in Spondyloarthropathy,” Annals of the Rheumatic Diseases 61, no. 6 (2002): 534–537.

[145] F. Tavasolian, S. Lively, C. Pastrello, et al., “Proteomic and Genomic Profiling of Plasma Exosomes From Patients With Ankylosing Spondylitis,” Annals of the Rheumatic Diseases 82, no. 11 (2023): 1429–1443.

[146] D. Liu, B. Liu, C. Lin, and J. Gu, “Imbalance of Peripheral Lymphocyte Subsets in Patients with Ankylosing Spondylitis: A Meta-Analysis,” Frontiers in Immunology 12 (2021): 696973.

[147] H. T. Liao and C. Y. Tsai, “Cytokines and Regulatory T Cells in Ankylosing Spondylitis,” Bone & Joint Research 12, no. 2 (2023): 133–137.

[148] D. Simone, F. Penkava, A. Ridley, S. Sansom, M. H. Al-Mossawi, and P. Bowness, “Single Cell Analysis of Spondyloarthritis Regulatory T Cells Identifies Distinct Synovial Gene Expression Patterns and Clonal Fates,” Communications Biology 4, no. 1 (2021): 1395.

[149] L. M. Araujo, I. Fert, Q. Jouhault, et al., “Increased Production of Interleukin-17 Over Interleukin-10 by Treg Cells Implicates Inducible Costimulator Molecule in Experimental Spondyloarthritis,” Arthritis & Rheumatology 66, no. 9 (2014): 2412–2422.

[150] Y. F. Liu, K. H. Zhuang, B. Chen, et al., “Expansion and Activation of Monocytic-myeloid-derived Suppressor Cell via STAT3/Arginase-I Signaling in Patients With Ankylosing Spondylitis,” Arthritis Research & Therapy 20, no. 1 (2018): 168.

[151] C. T. Ritchlin, R. A. Colbert, and D. D. Gladman, “Psoriatic Arthritis,” New England Journal of Medicine 376, no. 10 (2017): 957–970.

[152] D. J. Veale and U. Fearon, “The Pathogenesis of Psoriatic Arthritis,” Lancet 391, no. 10136 (2018): 2273–2284.

[153] O. FitzGerald, A. Ogdie, V. Chandran, et al., “Psoriatic Arthritis,” Nature Reviews Disease Primers 7, no. 1 (2021): 59.

[154] M. Kamata and Y. Tada, “Dendritic Cells and Macrophages in the Pathogenesis of Psoriasis,” Frontiers in Immunology 13 (2022): 941071.

[155] A. Deodhar, P. S. Helliwell, W. H. Boehncke, et al., “Guselkumab in Patients With Active Psoriatic Arthritis Who Were Biologic-naive or Had Previously Received TNFalpha Inhibitor Treatment (DISCOVER-1): A Double-blind, Randomised, Placebo-controlled Phase 3 Trial,” Lancet 395, no. 10230 (2020): 1115–1125.

[156] I. B. McInnes, A. Kavanaugh, A. B. Gottlieb, et al., “Efficacy and Safety of ustekinumab in Patients With Active Psoriatic Arthritis: 1 Year Results of the Phase 3, Multicentre, Double-blind, Placebo-controlled PSUMMIT 1 Trial,” Lancet 382, no. 9894 (2013): 780–789.

[157] P. J. Mease, P. Rahman, A. B. Gottlieb, et al., “Guselkumab in Biologic-naive Patients With Active Psoriatic Arthritis (DISCOVER-2): A Double-blind, Randomised, Placebo-controlled Phase 3 Trial,” Lancet 395, no. 10230 (2020): 1126–1136.

[158] C. Ritchlin, P. Rahman, A. Kavanaugh, et al., “Efficacy and Safety of the Anti-IL-12/23 p40 Monoclonal Antibody, ustekinumab, in Patients With Active Psoriatic Arthritis Despite Conventional Non-biological and Biological Anti-tumour Necrosis Factor Therapy: 6-month and 1-year Results of the Phase 3, Multicentre, Double-blind, Placebo-controlled, Randomised PSUMMIT 2 Trial,” Annals of the Rheumatic Diseases 73, no. 6 (2014): 990–999.

[159] H. Benham, P. Norris, J. Goodall, et al., “Th17 and Th22 Cells in Psoriatic Arthritis and Psoriasis,” Arthritis Research & Therapy 15, no. 5 (2013): R136.

[160] S. P. Raychaudhuri, S. K. Raychaudhuri, and M. C. Genovese, “IL-17 Receptor and Its Functional Significance in Psoriatic Arthritis,” Molecular and Cellular Biochemistry 359, no. 1-2 (2012): 419–429.

[161] C. T. Ritchlin and J. G. Krueger, “New Therapies for Psoriasis and Psoriatic Arthritis,” Current Opinion in Rheumatology 28, no. 3 (2016): 204–210.

[162] F. Ciccia, G. Guggino, A. Ferrante, et al., “Interleukin-9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients with Psoriatic Arthritis,” Arthritis & Rheumatology 68, no. 8 (2016): 1922–1931.

[163] W. Tillett, J. F. Merola, D. Thaci, et al., “Disease Characteristics and the Burden of Joint and Skin Involvement amongst People with Psoriatic Arthritis: A Population Survey,” Rheumatology and Therapy 7, no. 3 (2020): 617–637.

[164] P. E. Saw and E. Song, “The 'inflammazone' in Chronic Inflammatory Diseases: Psoriasis and Sarcoidosis,” Trends in Immunology 46, no. 2 (2025): 121–137.

[165] Q. Y. Su, S. X. Zhang, L. Yang, et al., “Peripheral T(reg) Levels and Transforming Growth Factor-beta (TGFbeta) in Patients With Psoriatic Arthritis: A Systematic Review Meta-Analysis,” Advances in Therapy 40, no. 1 (2023): 102–116.

[166] A. Szentpetery, E. Heffernan, M. Gogarty, et al., “Abatacept Reduces Synovial Regulatory T-cell Expression in Patients With Psoriatic Arthritis,” Arthritis Research & Therapy 19, no. 1 (2017): 158.

[167] T. McTaggart, J. X. Lim, K. J. Smith, et al., “Deep Phenotyping of T Regulatory Cells in Psoriatic Arthritis Highlights Targetable Mechanisms of Disease,” Journal of Biological Chemistry 301, no. 1 (2025): 108059.

[168] D. X. Nguyen, H. M. Baldwin, A. N. Ezeonyeji, M. R. Butt, and M. R. Ehrenstein, “Regulatory T Cells Enhance Th17 Migration in Psoriatic Arthritis Which Is Reversed by Anti-TNF,” Iscience 24, no. 9 (2021): 102973.

[169] T. Fukasawa, T. Yamashita, A. Enomoto, et al., “The Optimal Use of tildrakizumab in the Elderly via Improvement of Treg Function and Its Preventive Effect of Psoriatic Arthritis,” Frontiers in Immunology 14 (2023): 1286251.

[170] Y. Liu, W. Jarjour, N. Olsen, and S. G. Zheng, “Traitor or Warrior-Treg Cells Sneaking Into the Lesions of Psoriatic Arthritis,” Clinical Immunology 215 (2020): 108425.

[171] M. E. DeWane, R. Waldman, and J. Lu, “Dermatomyositis: Clinical Features and Pathogenesis,” Journal of the American Academy of Dermatology 82, no. 2 (2020): 267–281.

[172] M. C. Dalakas, “Inflammatory Muscle Diseases,” New England Journal of Medicine 372, no. 18 (2015): 1734–1747.

[173] R. Waldman, M. E. DeWane, and J. Lu, “Dermatomyositis: Diagnosis and Treatment,” Journal of the American Academy of Dermatology 82, no. 2 (2020): 283–296.

[174] Y. Ma, J. Lai, Q. Wan, Z. Chen, L. Sun, and Q. Zhang, “Identification of Common Mechanisms and Biomarkers for Dermatomyositis and Atherosclerosis Based on Bioinformatics Analysis,” Skin Research and Technology: Official Journal of International Society for Bioengineering and the Skin (Isbs) [And] International Society for Digital Imaging of Skin (Isdis) [And] International Society for Skin Imaging (Issi) 30, no. 6 (2024): e13808.

[175] Y. Zhang, L. Shan, D. Li, et al., “Identification of Key Biomarkers Associated With Immune Cells Infiltration for Myocardial Injury in Dermatomyositis by Integrated Bioinformatics Analysis,” Arthritis Research & Therapy 25, no. 1 (2023): 69.

[176] X. Lu, Q. Peng, and G. Wang, “Biomarkers of Disease Activity in Dermatomyositis,” Current Opinion in Rheumatology 34, no. 6 (2022): 289–294.

[177] X. Xu, T. Qiu, K. Sun, et al., “Integrated Analysis of Dermatomyositis Reveals Heterogeneous Immune Infiltration and Interstitial Lung Disease-associated Endotype,” Arthritis Research & Therapy 27, no. 1 (2025): 26.

[178] T. Jiang, Y. Huang, H. Liu, et al., “Reduced miR-146a Promotes REG3A Expression and Macrophage Migration in Polymyositis and Dermatomyositis,” Frontiers in Immunology 11 (2020): 37.

[179] A. Kokuzawa, J. Nakamura, Y. Kamata, and K. Sato, “Potential Role of Type I Interferon/IP-10 Axis in the Pathogenesis of Anti-MDA5 Antibody-positive Dermatomyositis,” Clinical and Experimental Rheumatology 41, no. 2 (2023): 275–284.

[180] M. Kogami, Y. Abe, T. Ando, A. Makiyama, K. Yamaji, and N. Tamura, “Changes in Anti-MDA5 Antibody Titres and Serum Cytokine Levels Before and After Diagnosis of Anti-MDA5 Antibody-positive Dermatomyositis,” Rheumatology 62, no. 7 (2023): 2525–2533.

[181] J. Shi, X. Pei, J. Peng, et al., “Monocyte-macrophage Dynamics as Key in Disparate Lung and Peripheral Immune Responses in Severe Anti-melanoma Differentiation-associated Gene 5-positive Dermatomyositis-related Interstitial Lung Disease,” Clinical and Translational Medicine 15, no. 2 (2025): e70226.

[182] W. Li, C. Deng, H. Yang, et al., “Expansion of Circulating Peripheral TIGIT+CD226+ CD4 T Cells With Enhanced Effector Functions in Dermatomyositis,” Arthritis Research & Therapy 23, no. 1 (2021): 15.

[183] X. Hou, C. Yang, M. Lin, et al., “Altered Peripheral Helper T Cells in Peripheral Blood and Muscle Tissue of the Patients With Dermatomyositis,” Clinical and Experimental Medicine 21, no. 4 (2021): 655–661.

[184] N. Okiyama, Y. Ichimura, M. Shobo, et al., “Immune Response to Dermatomyositis-specific Autoantigen, Transcriptional Intermediary Factor 1gamma Can Result in Experimental Myositis,” Annals of the Rheumatic Diseases 80, no. 9 (2021): 1201–1208.

[185] X. Chen, D. Lian, and H. Zeng, “Single-cell Profiling of Peripheral Blood and Muscle Cells Reveals Inflammatory Features of Juvenile Dermatomyositis,” Frontiers in Cell and Developmental Biology 11 (2023): 1166017.

[186] J. S. Gofshteyn, L. Mansfield, J. Spitznagle, et al., “Association of Juvenile Dermatomyositis Disease Activity with the Expansion of Blood Memory B and T Cell Subsets Lacking Follicular Markers,” Arthritis & Rheumatology 75, no. 7 (2023): 1246–1261.

[187] X. Lu, Q. Peng, and G. Wang, “Anti-MDA5 Antibody-positive Dermatomyositis: Pathogenesis and Clinical Progress,” Nature Reviews Rheumatology 20, no. 1 (2024): 48–62.

[188] Y. Guo, H. Liu, B. Chen, et al., “Dysregulated CD38 Expression on T Cells Was Associated With Rapidly Progressive Interstitial Lung Disease in Anti-melanoma Differentiation-associated Gene 5 Positive Dermatomyositis,” Frontiers in Immunology 15 (2024): 1455944.

[189] Y. Ye, Z. Chen, S. Jiang, et al., “Single-cell Profiling Reveals Distinct Adaptive Immune Hallmarks in MDA5+ Dermatomyositis With Therapeutic Implications,” Nature Communications 13, no. 1 (2022): 6458.

[190] Y. Zuo, L. Ye, F. Chen, et al., “Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome,” Frontiers in Immunology 13 (2022): 845988.

[191] M. Ogawa-Momohara, T. Vazquez, F. Chin, M. Sharma, J. Dan, and G. Sprow, “Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An in-depth, B-Cell-Directed Immunoprofile,” Journal of Investigative Dermatology 145, no. 1 (2025): 190–193. e2.

[192] J. He, Z. Liu, Y. Cao, et al., “Single-cell Landscape of Peripheral Immune Response in Patients With Anti-melanoma Differentiation-associated Gene 5 Dermatomyositis,” Rheumatology 63, no. 8 (2024): 2284–2294.

[193] O. Krystufkova, H. Hulejova, H. F. Mann, et al., “Serum Levels of B-cell Activating Factor of the TNF family (BAFF) Correlate With Anti-Jo-1 Autoantibodies Levels and Disease Activity in Patients With Anti-Jo-1positive Polymyositis and Dermatomyositis,” Arthritis Research & Therapy 20, no. 1 (2018): 158.

[194] Y. Shi, H. You, C. Liu, et al., “Elevated Serum B-cell Activator Factor Levels Predict Rapid Progressive Interstitial Lung Disease in Anti-melanoma Differentiation Associated Protein 5 Antibody Positive Dermatomyositis,” Orphanet Journal of Rare Diseases 19, no. 1 (2024): 170.

[195] C. Costin, A. Khojah, E. Ochfeld, et al., “B Cell Lymphocytosis in Juvenile Dermatomyositis,” Diagnostics (Basel) 13, no. 16 (2023): 2626.

[196] J. Radke, R. Koll, C. Preusse, et al., “Architectural B-cell Organization in Skeletal Muscle Identifies Subtypes of Dermatomyositis,” Neurology Neuroimmunology & Neuroinflammation 5, no. 3 (2018): e451.

[197] J. Neely, G. Hartoularos, D. Bunis, et al., “Multi-Modal Single-Cell Sequencing Identifies Cellular Immunophenotypes Associated with Juvenile Dermatomyositis Disease Activity,” Frontiers in Immunology 13 (2022): 902232.

[198] G. Rabadam, C. Wibrand, E. Flynn, et al., “Coordinated Immune Dysregulation in Juvenile Dermatomyositis Revealed by Single-cell Genomics,” JCI Insight 9, no. 12 (2024): e176963.

[199] C. J. M. Piper, M. G. L. Wilkinson, C. T. Deakin, et al., “CD19(+)CD24(hi)CD38(hi) B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype after Activation through Toll-Like Receptor 7 and Interferon-alpha,” Frontiers in Immunology 9 (2018): 1372.

[200] A. Bukhari, A. Khojah, W. Marin, et al., “Increased Otoferlin Expression in B Cells Is Associated With Muscle Weakness in Untreated Juvenile Dermatomyositis: A Pilot Study,” International Journal of Molecular Sciences 24, no. 13 (2023): 10553.

[201] F. Coutant, R. Bachet, J. J. Pin, M. Alonzo, and P. Miossec, “Monoclonal Antibodies From B Cells of Patients With Anti-MDA5 Antibody-positive Dermatomyositis Directly Stimulate Interferon Gamma Production,” Journal of Autoimmunity 130 (2022): 102831.

[202] R. Nicolai, P. Merli, P. Moran Alvarez, C. Bracaglia, F. Del Bufalo, and E. Marasco, “Autologous CD19-Targeting CAR T Cells in a Patient with Refractory Juvenile Dermatomyositis,” Arthritis & Rheumatology 76, no. 10 (2024): 1560–1565.

[203] A. Paris-Munoz, R. M. Alcobendas-Rueda, C. Verdu-Sanchez, et al., “CD19 CAR-T Cell Therapy in a Pediatric Patient With MDA5(+) Dermatomyositis and Rapidly Progressive Interstitial Lung Disease,” Med 6, no. 8 (2025): 100676.

[204] Y. Liu, Y. Li, T. Shen, et al., “Belimumab Ameliorates Symptoms and Disease Activity in Patients With Dermatomyositis and Juvenile Dermatomyositis Refractory to Standard Therapy: A Retrospective Observational Study,” Journal of the American Academy of Dermatology 91, no. 3 (2024): 524–527.

[205] M. T. Holzer, J. F. Nies, T. Oqueka, T. B. Huber, I. Kotter, and M. Krusche, “Successful Rescue Therapy with Daratumumab in Rapidly Progressive Interstitial Lung Disease Caused by MDA5-Positive Dermatomyositis,” Chest 163, no. 1 (2023): e1–e5.

[206] E. Antiga, C. C. Kretz, R. Klembt, et al., “Characterization of Regulatory T Cells in Patients With Dermatomyositis,” Journal of Autoimmunity 35, no. 4 (2010): 342–350.

[207] M. Feng, H. Guo, C. Zhang, et al., “Absolute Reduction of Regulatory T Cells and Regulatory Effect of Short-term and Low-dose IL-2 in Polymyositis or Dermatomyositis,” International Immunopharmacology 77 (2019): 105912.

[208] S. X. Zhang, J. Wang, H. H. Sun, et al., “Circulating Regulatory T Cells Were Absolutely Decreased in Dermatomyositis/Polymyositis Patients and Restored by Low-dose IL-2,” Annals of the Rheumatic Diseases 80, no. 8 (2021): e130.

[209] Y. Xie, T. Zhang, R. Su, et al., “Increased Serum Soluble Interleukin-2 Receptor Levels in Dermatomyositis Are Associated With Th17/Treg Immune Imbalance,” Clinical and Experimental Medicine 23, no. 7 (2023): 3605–3617.

[210] Z. Zhang, J. Pang, Y. Li, Y. Zuo, X. Cui, and H. Xu, “Imbalance of Peripheral Blood Th17/Treg Increases Neutrophil-to-lymphocyte Ratio in Patients With Dermatomyositis,” American Journal of Translational Research 15, no. 10 (2023): 6106–6114.

[211] X. Zheng, R. Su, F. Hu, et al., “Low-dose IL-2 Therapy Restores Imbalance Between Th17 and Regulatory T Cells in Patients With the Dermatomyositis Combined With EBV/CMV Viremia,” Autoimmunity Reviews 21, no. 11 (2022): 103186.

[212] E. Sag, G. Kale, G. Haliloglu, et al., “Inflammatory Milieu of Muscle Biopsies in Juvenile Dermatomyositis,” Rheumatology International 41, no. 1 (2021): 77–85.

[213] Y. Vercoulen, F. Bellutti Enders, J. Meerding, M. Plantinga, E. F. Elst, and H. Varsani, “Increased Presence of FOXP3+ Regulatory T Cells in Inflamed Muscle of Patients With Active Juvenile Dermatomyositis Compared to Peripheral Blood,” PLoS ONE 9, no. 8 (2014): e105353.

[214] Y. Chen, H. Liu, Z. Luo, et al., “ASM Is a Therapeutic Target in Dermatomyositis by Regulating the Differentiation of Naive CD4+T Cells Into Th17 and Treg Subsets,” Skeletal Muscle 14, no. 1 (2024): 16.

[215] W. Yan, L. Wang, Z. Chen, et al., “Knockdown of lncRNA HAGLR Promotes Treg Cell Differentiation Through Increasing the RUNX3 Level in Dermatomyositis,” Journal of Molecular Histology 53, no. 2 (2022): 413–421.

[216] J. M. Pandya, I. Loell, M. S. Hossain, et al., “Effects of Conventional Immunosuppressive Treatment on CD244+ (CD28null) and FOXP3+ T Cells in the Inflamed Muscle of Patients With Polymyositis and Dermatomyositis,” Arthritis Research & Therapy 18 (2016): 80.

[217] I. E. Lundberg, M. Fujimoto, J. Vencovsky, et al., “Idiopathic Inflammatory Myopathies,” Nature Reviews Disease Primers 7, no. 1 (2021): 86.

[218] V. Leclair, A. Notarnicola, J. Vencovsky, and I. E. Lundberg, “Polymyositis: Does It Really Exist as a Distinct Clinical Subset?,” Current Opinion in Rheumatology 33, no. 6 (2021): 537–543.

[219] Q. Jia, R. J. Hao, X. J. Lu, et al., “Identification of Hub Biomarkers and Immune Cell Infiltration Characteristics of Polymyositis by Bioinformatics Analysis,” Frontiers in Immunology 13 (2022): 1002500.

[220] M. Kamiya, F. Mizoguchi, A. Takamura, N. Kimura, K. Kawahata, and H. Kohsaka, “A New in Vitro Model of Polymyositis Reveals CD8+ T Cell Invasion Into Muscle Cells and Its Cytotoxic Role,” Rheumatology 59, no. 1 (2020): 224–232.

[221] M. Houtman, L. Ekholm, E. Hesselberg, et al., “T-cell Transcriptomics From Peripheral Blood Highlights Differences Between Polymyositis and Dermatomyositis Patients,” Arthritis Research & Therapy 20, no. 1 (2018): 188.

[222] Y. Shimojima, M. Matsuda, W. Ishii, D. Kishida, and Y. Sekijima, “T-cell Receptor-mediated Characteristic Signaling Pathway of Peripheral Blood T Cells in Dermatomyositis and Polymyositis,” Autoimmunity 50, no. 8 (2017): 481–490.

[223] Z. Zhu, C. Yang, J. Wang, Q. Feng, Q. Chen, and P. Yang, “Altered Chemokine Receptor Expression in the Peripheral Blood Lymphocytes in Polymyositis and Dermatomyositis,” Cytokine 99 (2017): 316–321.

[224] H. Hasegawa, K. Kawahata, F. Mizoguchi, N. Okiyama, N. Miyasaka, and H. Kohsaka, “Direct Suppression of Autoaggressive CD8+ T Cells With CD80/86 Blockade in CD8+ T Cell-mediated Polymyositis Models of Mice,” Clinical and Experimental Rheumatology 35, no. 4 (2017): 593–597.

[225] J. M. Pandya, P. Venalis, L. Al-Khalili, et al., “CD4+ and CD8+ CD28(null) T Cells Are Cytotoxic to Autologous Muscle Cells in Patients with Polymyositis,” Arthritis & Rheumatology 68, no. 8 (2016): 2016–2026.

[226] S. John, S. J. Antonia, T. A. Rose, et al., “Progressive Hypoventilation due to Mixed CD8(+) and CD4(+) Lymphocytic Polymyositis Following tremelimumab—durvalumab Treatment,” Journal for ImmunoTherapy of Cancer 5, no. 1 (2017): 54.

[227] T. Kimura, S. Fukushima, A. Miyashita, et al., “Myasthenic Crisis and Polymyositis Induced by One Dose of nivolumab,” Cancer Science 107, no. 7 (2016): 1055–1058.

[228] P. Xia, Y. Q. Shao, C. C. Yu, Y. Xie, and Z. J. Zhou, “NLRP3 inflammasome Up-regulates Major Histocompatibility Complex Class I Expression and Promotes Inflammatory Infiltration in Polymyositis,” BMC Immunology [Electronic Resource] 23, no. 1 (2022): 39.

[229] W. Yan, C. Chen, and H. Chen, “Estrogen Downregulates miR-21 Expression and Induces Inflammatory Infiltration of Macrophages in Polymyositis: Role of CXCL10,” Molecular Neurobiology 54, no. 3 (2017): 1631–1641.

[230] W. Yan, W. Fan, C. Chen, Y. Wu, Z. Fan, and J. Chen, “IL-15 Up-regulates the MMP-9 Expression Levels and Induces Inflammatory Infiltration of Macrophages in Polymyositis Through Regulating the NF-kB Pathway,” Gene 591, no. 1 (2016): 137–147.

[231] Y. Liu, Y. Gao, J. Yang, C. Shi, Y. Wang, and Y. Xu, “MicroRNA-381 Reduces Inflammation and Infiltration of Macrophages in Polymyositis via Downregulating HMGB1,” International Journal of Oncology 53, no. 3 (2018): 1332–1342.

[232] D. Wu, Y. Cui, Y. Cao, et al., “Clinical Implications and Mechanism of Complement C1q in Polymyositis,” Applied Biochemistry and Biotechnology 196, no. 6 (2024): 3088–3101.

[233] Y. Zhou, Y. Zhao, G. Yin, L. Kang, X. Zhu, and Q. Xie, “CD44 is Associated With Muscle Inflammation in Polymyositis and Skin Damage in Idiopathic Inflammatory Myopathy,” Clinical and Experimental Rheumatology 43, no. 2 (2025): 241–250.

[234] Y. Enomoto, Y. Suzuki, H. Hozumi, et al., “Clinical Significance of Soluble CD163 in Polymyositis-related or Dermatomyositis-related Interstitial Lung Disease,” Arthritis Research & Therapy 19, no. 1 (2017): 9.

[235] Q. L. Peng, Y. L. Zhang, X. M. Shu, et al., “Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated With Macrophage Infiltration in Muscle Tissue,” Journal of Rheumatology 42, no. 6 (2015): 979–987.

[236] X. Yang, H. Yao, Q. Zhao, et al., “UNC13D mutation in a Patient With Juvenile Polymyositis With Recurrent Macrophage Activation Syndrome,” Rheumatology 60, no. 11 (2021): e404–e406.

[237] S. Koh, H. Koh, Y. Nakashima, et al., “Plasma Kinetics of Th1, Th2 and Th17 Cytokines in Polymyositis Related to Chronic Graft-versus-Host Disease,” Internal Medicine 55, no. 16 (2016): 2265–2270.

[238] R. Anan, M. Akiyama, Y. Kaneko, et al., “Polymyositis With Elevated Serum IgG4 Levels and Abundant IgG4+ Plasma Cell Infiltration: A Case Report and Literature Review,” Medicine 96, no. 48 (2017): e8710.

[239] A. Tjarnlund, Q. Tang, C. Wick, et al., “Abatacept in the Treatment of Adult Dermatomyositis and Polymyositis: A Randomised, Phase IIb Treatment Delayed-start Trial,” Annals of the Rheumatic Diseases 77, no. 1 (2018): 55–62.

[240] J. Zhao, X. J. Guo, and L. Shi, “Inflammatory Biomarkers in Polymyositis/Dermatomyositis Patients With Interstitial Lung Disease: A Retrospective Study,” Current Medical Research and Opinion 40, no. 1 (2024): 113–122.

[241] D. J. Hunter, L. March, and M. Chew, “Osteoarthritis in 2020 and Beyond: A Lancet Commission,” Lancet 396, no. 10264 (2020): 1711–1712.

[242] F. Motta, E. Barone, A. Sica, and C. Selmi, “Inflammaging and Osteoarthritis,” Clinical Reviews in Allergy & Immunology 64, no. 2 (2023): 222–238.

[243] N. Amos, S. Lauder, A. Evans, M. Feldmann, and J. Bondeson, “Adenoviral Gene Transfer Into Osteoarthritis Synovial Cells Using the Endogenous Inhibitor IkappaBalpha Reveals That Most, but Not All, Inflammatory and Destructive Mediators Are NFkappaB Dependent,” Rheumatology 45, no. 10 (2006): 1201–1209.

[244] W. C. Chang, M. T. Chu, C. Y. Hsu, et al., “Rhein, an Anthraquinone Drug, Suppresses the NLRP3 Inflammasome and Macrophage Activation in Urate Crystal-Induced Gouty Inflammation,” American Journal of Chinese Medicine 47, no. 1 (2019): 135–151.

[245] J. Sokolove and C. M. Lepus, “Role of Inflammation in the Pathogenesis of Osteoarthritis: Latest Findings and Interpretations,” Therapeutic Advances in Musculoskeletal Disease 5, no. 2 (2013): 77–94.

[246] H. Zhang, D. Cai, and X. Bai, “Macrophages Regulate the Progression of Osteoarthritis,” Osteoarthritis and Cartilage 28, no. 5 (2020): 555–561.

[247] S. Samavedi, P. Diaz-Rodriguez, J. D. Erndt-Marino, and M. S. Hahn, “A Three-Dimensional Chondrocyte-Macrophage Coculture System to Probe Inflammation in Experimental Osteoarthritis,” Tissue Engineering Part A 23, no. 3-4 (2017): 101–114.

[248] E. N. Blaney Davidson, P. M. van der Kraan, and W. B. van den Berg, “TGF-beta and Osteoarthritis,” Osteoarthritis and Cartilage 15, no. 6 (2007): 597–604.

[249] H. Zhang, C. Lin, C. Zeng, et al., “Synovial Macrophage M1 Polarisation Exacerbates Experimental Osteoarthritis Partially Through R-spondin-2,” Annals of the Rheumatic Diseases 77, no. 10 (2018): 1524–1534.

[250] A. B. Blom, P. L. van Lent, A. E. Holthuysen, et al., “Synovial Lining Macrophages Mediate Osteophyte Formation During Experimental Osteoarthritis,” Osteoarthritis and Cartilage 12, no. 8 (2004): 627–635.

[251] A. B. Blom, P. L. van Lent, S. Libregts, et al., “Crucial Role of Macrophages in Matrix Metalloproteinase-mediated Cartilage Destruction During Experimental Osteoarthritis: Involvement of Matrix Metalloproteinase 3,” Arthritis and Rheumatism 56, no. 1 (2007): 147–157.

[252] C. L. Wu, J. McNeill, K. Goon, et al., “Conditional Macrophage Depletion Increases Inflammation and Does Not Inhibit the Development of Osteoarthritis in Obese Macrophage Fas-Induced Apoptosis-Transgenic Mice,” Arthritis & Rheumatology 69, no. 9 (2017): 1772–1783.

[253] B. Liu, M. Zhang, J. Zhao, M. Zheng, and H. Yang, “Imbalance of M1/M2 Macrophages Is Linked to Severity Level of Knee Osteoarthritis,” Experimental and Therapeutic Medicine 16, no. 6 (2018): 5009–5014.

[254] A. Damerau, E. Rosenow, D. Alkhoury, F. Buttgereit, and T. Gaber, “Fibrotic Pathways and Fibroblast-Like Synoviocyte Phenotypes in Osteoarthritis,” Frontiers in Immunology 15 (2024): 1385006.

[255] D. Han, Y. Fang, X. Tan, et al., “The Emerging Role of Fibroblast-Like Synoviocytes-mediated Synovitis in Osteoarthritis: An Update,” Journal of Cellular and Molecular Medicine 24, no. 17 (2020): 9518–9532.

[256] A. Koskinen, K. Vuolteenaho, T. Moilanen, and E. Moilanen, “Resistin as a Factor in Osteoarthritis: Synovial Fluid Resistin Concentrations Correlate Positively With Interleukin 6 and Matrix Metalloproteinases MMP-1 and MMP-3,” Scandinavian Journal of Rheumatology 43, no. 3 (2014): 249–253.

[257] S. Kemble and A. P. Croft, “Critical Role of Synovial Tissue-Resident Macrophage and Fibroblast Subsets in the Persistence of Joint Inflammation,” Frontiers in Immunology 12 (2021): 715894.

[258] F. Zhang, K. Wei, K. Slowikowski, et al., “Defining Inflammatory Cell States in Rheumatoid Arthritis Joint Synovial Tissues by Integrating Single-cell Transcriptomics and Mass Cytometry,” Nature Immunology 20, no. 7 (2019): 928–942.

[259] T. W. Kragstrup, D. H. Sohn, C. M. Lepus, et al., “Fibroblast-Like Synovial Cell Production of Extra Domain A Fibronectin Associates With Inflammation in Osteoarthritis,” BMC Rheumatology 3 (2019): 46.

[260] N. Xie, Z. Tan, S. Banerjee, et al., “Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis,” American Journal of Respiratory and Critical Care Medicine 192, no. 12 (2015): 1462–1474.

[261] L. Zheng, Z. Zhang, P. Sheng, and A. Mobasheri, “The Role of Metabolism in Chondrocyte Dysfunction and the Progression of Osteoarthritis,” Ageing Research Reviews 66 (2021): 101249.

[262] F. Mizoguchi, K. Slowikowski, K. Wei, et al., “Functionally Distinct Disease-associated Fibroblast Subsets in Rheumatoid Arthritis,” Nature Communications 9, no. 1 (2018): 789.

[263] J. Massague and D. Sheppard, “TGF-beta Signaling in Health and Disease,” Cell 186, no. 19 (2023): 4007–4037.

[264] S. Pacquelet, N. Presle, C. Boileau, et al., “Interleukin 17, a Nitric Oxide-producing Cytokine With a Peroxynitrite-independent Inhibitory Effect on Proteoglycan Synthesis,” Journal of Rheumatology 29, no. 12 (2002): 2602–2610.

[265] W. Sun, X. Li, L. Zhang, et al., “IL-17A Exacerbates Synovial Inflammation in Osteoarthritis via Activation of Endoplasmic Reticulum Stress,” International Immunopharmacology 145 (2025): 113733.

[266] D. Sinkeviciute, A. Aspberg, Y. He, A. C. Bay-Jensen, and P. Onnerfjord, “Characterization of the Interleukin-17 Effect on Articular Cartilage in a Translational Model: An Explorative Study,” BMC Rheumatology 4 (2020): 30.

[267] E. Wisniewska, D. Laue, J. Spinnen, et al., “Infrapatellar Fat Pad Modulates Osteoarthritis-Associated Cytokine and MMP Expression in Human Articular Chondrocytes,” Cells 12, no. 24 (2023): 2850.

[268] J. Apinun, P. Sengprasert, P. Yuktanandana, S. Ngarmukos, A. Tanavalee, and R. Reantragoon, “Immune Mediators in Osteoarthritis: Infrapatellar Fat Pad-Infiltrating CD8+ T Cells Are Increased in Osteoarthritic Patients With Higher Clinical Radiographic Grading,” International Journal of Rheumatology 2016 (2016): 9525724.

[269] N. Zapata-Linares, L. Loisay, D. de Haro, et al., “Systemic and Joint Adipose Tissue Lipids and Their Role in Osteoarthritis,” Biochimie 227, no. Pt B (2024): 130–138.

[270] H. Platzer, R. Trauth, T. A. Nees, et al., “CD8(+) T Cells in OA Knee Joints Are Differentiated Into Subsets Depending on OA Stage and Compartment,” Journal of Clinical Medicine 11, no. 10 (2022): 2814.

[271] M. A. Boutet, A. Nerviani, L. Fossati-Jimack, et al., “Comparative Analysis of Late-stage Rheumatoid Arthritis and Osteoarthritis Reveals Shared Histopathological Features,” Osteoarthritis and Cartilage 32, no. 2 (2024): 166–176.

[272] Z. Wen, L. Qiu, Z. Ye, et al., “The Role of Th/Treg Immune Cells in Osteoarthritis,” Frontiers in Immunology 15 (2024): 1393418.

[273] L. E. Keller, E. D. Tait Wojno, L. Begum, and L. A. Fortier, “Regulatory T Cells Provide Chondroprotection Through Increased TIMP1, IL-10 and IL-4, but CannotNot Mitigate the Catabolic Effects of IL-1beta and IL-6 in a Tri-culture Model of Osteoarthritis,” Osteoarthritis and Cartilage Open 3, no. 3 (2021): 100193.

[274] N. Rosshirt, R. Trauth, H. Platzer, et al., “Proinflammatory T Cell Polarization Is Already Present in Patients With Early Knee Osteoarthritis,” Arthritis Research & Therapy 23, no. 1 (2021): 37.

[275] H. Luo, Y. Zhu, B. Guo, et al., “Causal Relationships Between CD25 on Immune Cells and Hip Osteoarthritis,” Frontiers in Immunology 14 (2023): 1247710.

[276] T. A. Nees, J. A. Zhang, H. Platzer, et al., “Infiltration Profile of Regulatory T Cells in Osteoarthritis-Related Pain and Disability,” Biomedicines 10, no. 9 (2022): 2111.

[277] S. Li, J. Wan, W. Anderson, H. Sun, H. Zhang, and X. Peng, “Downregulation of IL-10 Secretion by Treg Cells in Osteoarthritis Is Associated With a Reduction in Tim-3 Expression,” Biomedicine & Pharmacotherapy 79 (2016): 159–165.

[278] C. Xu, S. Wang, X. Chen, et al., “Causal Associations Between Circulating Immune Cells and Osteoarthritis: A Bidirectional Mendelian Randomization Study,” International Immunopharmacology 142, no. Pt A (2024): 113156.

[279] M. Atabaki, Z. Shariati-Sarabi, J. Tavakkol-Afshari, and M. Mohammadi, “Significant Immunomodulatory Properties of Curcumin in Patients With Osteoarthritis; a Successful Clinical Trial in Iran,” International Immunopharmacology 85 (2020): 106607.

[280] H. Sun, Y. Zhang, W. Song, et al., “IgM(+)CD27(+) B Cells Possessed Regulatory Function and Represented the Main Source of B Cell-derived IL-10 in the Synovial Fluid of Osteoarthritis Patients,” Human Immunology 80, no. 4 (2019): 263–269.

[281] D. M. Black and C. J. Rosen, “Clinical Practice. Postmenopausal Osteoporosis,” New England Journal of Medicine 374, no. 3 (2016): 254–262.

[282] Y. W. Zhang, M. M. Cao, Y. J. Li, et al., “Dietary Protein Intake in Relation to the Risk of Osteoporosis in Middle-Aged and Older Individuals: A Cross-Sectional Study,” Journal of Nutrition, Health and Aging 26, no. 3 (2022): 252–258.

[283] L. Sapra, C. Saini, P. K. Mishra, et al., “Bacillus Coagulans Ameliorates Inflammatory Bone Loss in Post-menopausal Osteoporosis via Modulating the "Gut-Immune-Bone" Axis,” Gut Microbes 17, no. 1 (2025): 2492378.

[284] S. Song, Y. Guo, Y. Yang, and D. Fu, “Advances in Pathogenesis and Therapeutic Strategies for Osteoporosis,” Pharmacology & Therapeutics 237 (2022): 108168.

[285] J. Munoz, N. S. Akhavan, A. P. Mullins, and B. H. Arjmandi, “Macrophage Polarization and Osteoporosis: A Review,” Nutrients 12, no. 10 (2020): 2999.

[286] J. Tsay, Z. Yang, F. P. Ross, et al., “Bone Loss Caused by Iron Overload in a Murine Model: Importance of Oxidative Stress,” Blood 116, no. 14 (2010): 2582–2589.

[287] J. L. Kirkland and T. Tchkonia, “Senolytic Drugs: From Discovery to Translation,” Journal of Internal Medicine 288, no. 5 (2020): 518–536.

[288] Y. Sun, J. Li, X. Xie, et al., “Macrophage-Osteoclast Associations: Origin, Polarization, and Subgroups,” Frontiers in Immunology 12 (2021): 778078.

[289] R. Pacifici, “Role of Gut Microbiota in the Skeletal Response to PTH,” Journal of Clinical Endocrinology and Metabolism 106, no. 3 (2021): 636–645.

[290] M. Yu, A. Malik Tyagi, J. Y. Li, J. Adams, T. L. Denning, and M. N. Weitzmann, “PTH Induces Bone Loss via Microbial-dependent Expansion of Intestinal TNF(+) T Cells and Th17 Cells,” Nature Communications 11, no. 1 (2020): 468.

[291] F. An, X. Jia, Y. Shi, X. Xiao, F. Yang, and J. Su, “The Ultimate Microbial Composition for Correcting Th17/Treg Cell Imbalance and Lipid Metabolism Disorders in Osteoporosis,” International Immunopharmacology 144 (2025): 113613.

[292] W. Zhang, W. Zhao, W. Li, et al., “The Imbalance of Cytokines and Lower Levels of Tregs in Elderly Male Primary Osteoporosis,” Frontiers in Endocrinolog (Lausanne) 13 (2022): 779264.

[293] X. Yang, F. Zhou, P. Yuan, et al., “T Cell-depleting Nanoparticles Ameliorate Bone Loss by Reducing Activated T Cells and Regulating the Treg/Th17 Balance,” Bioactive Materials 6, no. 10 (2021): 3150–3163.

[294] F. Huang, P. Wong, J. Li, et al., “Osteoimmunology: The Correlation Between Osteoclasts and the Th17/Treg Balance in Osteoporosis,” Journal of Cellular and Molecular Medicine 26, no. 13 (2022): 3591–3597.

[295] A. Taylor, J. Verhagen, K. Blaser, M. Akdis, and C. A. Akdis, “Mechanisms of Immune Suppression by Interleukin-10 and Transforming Growth Factor-beta: The Role of T Regulatory Cells,” Immunology 117, no. 4 (2006): 433–442.

[296] C. F. Francisconi, A. E. Vieira, M. C. S. Azevedo, et al., “RANKL Triggers Treg-Mediated Immunoregulation in Inflammatory Osteolysis,” Journal of Dental Research 97, no. 8 (2018): 917–927.

[297] L. Sapra, H. Y. Dar, A. Bhardwaj, et al., “Lactobacillus Rhamnosus Attenuates Bone Loss and Maintains Bone Health by Skewing Treg-Th17 Cell Balance in Ovx Mice,” Scientific Reports 11, no. 1 (2021): 1807.

[298] H. Y. Dar, S. Pal, P. Shukla, et al., “Bacillus Clausii Inhibits Bone Loss by Skewing Treg-Th17 Cell Equilibrium in Postmenopausal Osteoporotic Mice Model,” Nutrition (Burbank, Los Angeles County, Calif) 54 (2018): 118–128.

[299] J. Piao, J. S. Park, D. Y. Hwang, Y. Son, and H. S. Hong, “Substance P Blocks Ovariectomy-induced Bone Loss by Modulating Inflammation and Potentiating Stem Cell Function,” Aging (Albany NY) 12, no. 20 (2020): 20753–20777.

[300] L. Sapra, A. Bhardwaj, P. K. Mishra, et al., “Regulatory B Cells (Bregs) Inhibit Osteoclastogenesis and Play a Potential Role in Ameliorating Ovariectomy-Induced Bone Loss,” Frontiers in Immunology 12 (2021): 691081.

[301] D. Frase, C. Lee, C. Nachiappan, R. Gupta, and A. Akkouch, “The Inflammatory Contribution of B-Lymphocytes and Neutrophils in Progression to Osteoporosis,” Cells 12, no. 13 (2023): 1744.

[302] L. Sapra, C. Saini, P. K. Mishra, B. Garg, M. Gupta, and R. K. Srivastava, “Compromised Anti-osteoclastogenic and Immunomodulatory Functions of Regulatory B Cells (Bregs) Aggravate Inflammatory Bone Loss in Post-menopausal Osteoporosis,” Biochimica et Biophysica Acta: Molecular Basis of Disease 1871, no. 3 (2025): 167675.

[303] Y. Wang, W. Zhang, S. M. Lim, L. Xu, and J. O. Jin, “Interleukin-10-Producing B Cells Help Suppress Ovariectomy-Mediated Osteoporosis,” Immune Network 20, no. 6 (2020): e50.

[304] L. Sapra, N. Shokeen, K. Porwal, et al., “Bifidobacterium Longum Ameliorates Ovariectomy-Induced Bone Loss via Enhancing Anti-Osteoclastogenic and Immunomodulatory Potential of Regulatory B Cells (Bregs),” Frontiers in Immunology 13 (2022): 875788.

[305] X. Chen, A. Zhang, K. Zhao, et al., “The Role of Oxidative Stress in Intervertebral Disc Degeneration: Mechanisms and Therapeutic Implications,” Ageing Research Reviews 98 (2024): 102323.

[306] L. Kang, H. Zhang, C. Jia, R. Zhang, and C. Shen, “Epigenetic Modifications of Inflammation in Intervertebral Disc Degeneration,” Ageing Research Reviews 87 (2023): 101902.

[307] X. Kong, H. Gu, Y. Zhang, et al., “beta-Mangostin Attenuates TET2-Mediated DNA Demethylation of Prkcg in the Prevention of Intervertebral Disc Degeneration,” Advanced science (Weinheim) 12, no. 32 (2025): e05077.

[308] Y. Huang, H. Li, L. Qi, et al., “NanoCRISPR-assisted Biomimetic Tissue-equivalent Patch Regenerates the Intervertebral Disc by Inhibiting Endothelial-to-mesenchymal Transition,” Biomaterials 322 (2025): 123404.

[309] K. G. Burt, M. K. M. Kim, D. C. Viola, A. C. Abraham, and N. O. Chahine, “Nuclear Factor kappaB Overactivation in the Intervertebral Disc Leads to Macrophage Recruitment and Severe Disc Degeneration,” Science Advances 10, no. 23 (2024): eadj3194.

[310] X. Zhao, Z. Sun, B. Xu, et al., “Degenerated Nucleus Pulposus Cells Derived Exosome Carrying miR-27a-3p Aggravates Intervertebral Disc Degeneration by Inducing M1 Polarization of Macrophages,” Journal of Nanobiotechnology 21, no. 1 (2023): 317.

[311] Y. Fu, H. Sun, Y. Jin, S. Cheng, Y. Wu, and C. Liu, “Self-assembled Antioxidant Enzyme-mimicking Hydrogel: Targeting Oxidative Stress and Macrophage Organization for Improving Degenerated Intervertebral Discs,” Materials Today Bio 31 (2025): 101586.

[312] Y. Dou, Y. Zhang, Y. Liu, et al., “Role of Macrophage in Intervertebral Disc Degeneration,” Bone Research 13, no. 1 (2025): 15.

[313] X. C. Li, S. J. Luo, W. Fan, T. L. Zhou, D. Q. Tan, and R. X. Tan, “Macrophage Polarization Regulates Intervertebral Disc Degeneration by Modulating Cell Proliferation, Inflammation Mediator Secretion, and Extracellular Matrix Metabolism,” Frontiers in Immunology 13 (2022): 922173.

[314] F. Li, Y. Shi, J. Chen, et al., “LGR6 modulates Intervertebral Disc Degeneration Through Regulation of Macrophage Efferocytosis,” Journal of Translational Medicine 23, no. 1 (2025): 475.

[315] X. J. Yu, P. Zou, T. Q. Li, et al., “Deciphering SPP1-related Macrophage Signaling in the Pathogenesis of Intervertebral Disc Degeneration,” Cell Biology and Toxicology 41, no. 1 (2025): 33.

[316] Y. Zhang, J. Zhang, Z. Sun, et al., “MAPK8 and CAPN1 as Potential Biomarkers of Intervertebral Disc Degeneration Overlapping Immune Infiltration, Autophagy, and ceRNA,” Frontiers in Immunology 14 (2023): 1188774.

[317] S. W. Clayton, R. E. Walk, L. Mpofu, G. W. D. Easson, and S. Y. Tang, “Sex-specific Divergences in the Types and Timing of Infiltrating Immune Cells During the Intervertebral Disc Acute Injury Response and Their Associations With Degeneration,” Osteoarthritis and Cartilage 33, no. 2 (2025): 247–260.

[318] C. Xu, M. Zhang, K. Li, et al., “CD24(hi)CD38(hi) B Regulatory Cells From Patients With End Plate Inflammation Presented Reduced Functional Potency,” International Immunopharmacology 70 (2019): 295–301.

[319] K. Guo, J. Zeng, J. Lu, et al., “The Clinical Significance of the Neutrophil-to-Lymphocyte Ratio as a Novel Inflammatory Biomarker for Assessing the Severity of Intervertebral Disc Degeneration,” Frontiers in Medicine (Lausanne) 11 (2024): 1446124.

[320] T. L. Zhang, W. K. Chen, X. P. Huang, et al., “Single-cell RNA Sequencing Reveals the MIF/ACKR3 Receptor-ligand Interaction Between Neutrophils and Nucleus Pulposus Cells in Intervertebral Disc Degeneration,” Translational Research 272 (2024): 1–18.

[321] B. Song, J. Wang, H. Tang, H. Li, and W. Zhang, “Shared Diagnostic Genes and Potential Mechanisms Between Intervertebral Disc Degeneration and Diabetes Mellitus Revealed by Integrated Transcriptomic Analysis and Machine Learning,” Frontiers in Endocrinology (Lausanne) 16 (2025): 1576826.

[322] W. Li, Z. Ding, H. Zhang, et al., “The Roles of Blood Lipid-Metabolism Genes in Immune Infiltration Could Promote the Development of IDD,” Frontiers in Cell and Developmental Biology 10 (2022): 844395.

[323] T. Shao, Q. Gao, W. Tang, Y. Ma, J. Gu, and Z. Yu, “The Role of Immunocyte Infiltration Regulatory Network Based on hdWGCNA and Single-Cell Bioinformatics Analysis in Intervertebral Disc Degeneration,” Inflammation 47, no. 6 (2024): 1987–1999.

[324] Y. Yamamoto, Y. Kokubo, H. Nakajima, K. Honjoh, S. Watanabe, and A. Matsumine, “Distribution and Polarization of Hematogenous Macrophages Associated With the Progression of Intervertebral Disc Degeneration,” Spine (Phila Pa 1976) 47, no. 4 (2022): E149–E158.

[325] X. C. Li, W. Wang, C. Jiang, et al., “CD206(+) M2-Like Macrophages Protect Against Intervertebral Disc Degeneration Partially by Targeting R-spondin-2,” Osteoarthritis and Cartilage 32, no. 1 (2024): 66–81.

[326] Z. Tao, T. Zhang, Y. Ge, et al., “M2 macrophages Regulate Nucleus Pulposus Cell Extracellular Matrix Synthesis Through the OPN-CD44 Axis in Intervertebral Disc Degeneration,” Osteoarthritis and Cartilage 33, no. 4 (2025): 447–460.

[327] X. C. Li, S. J. Luo, W. Fan, T. L. Zhou, C. M. Huang, and M. S. Wang, “M2 macrophage-conditioned Medium Inhibits Intervertebral Disc Degeneration in a Tumor Necrosis Factor-alpha-rich Environment,” Journal of Orthopaedic Research 40, no. 11 (2022): 2488–2501.

[328] Y. Liu, M. Xue, Y. Han, Y. Li, B. Xiao, and W. Wang, “Exosomes From M2c Macrophages Alleviate Intervertebral Disc Degeneration by Promoting Synthesis of the Extracellular Matrix via MiR-124/CILP/TGF-beta,” Bioengineering & Translational Medicine 8, no. 6 (2023): e10500.

[329] K. Zhang, L. Du, Z. Li, et al., “M2 Macrophage-Derived Small Extracellular Vesicles Ameliorate Pyroptosis and Intervertebral Disc Degeneration,” Biomaterials Research 28 (2024): 0047.

[330] S. P. Zhang, M. Tong, J. Mo, Z. Y. Dong, and Y. F. Huang, “M2 macrophages Activate the IL-10/JAK2/STAT3 Pathway to Induce Pathological Microangiogenesis in the Nucleus Pulposus Exacerbating Intervertebral Disc Degeneration,” Journal of Orthopaedic Surgery and Research 20, no. 1 (2025): 532.

[331] J. Qian, X. Wang, G. Su, et al., “Platelet-rich Plasma-derived Exosomes Attenuate Intervertebral Disc Degeneration by Promoting NLRP3 Autophagic Degradation in Macrophages,” International Immunopharmacology 110 (2022): 108962.

[332] J. Luo, G. Jin, S. Cui, H. Wang, and Q. Liu, “Regulatory Mechanism of FCGR2A in Macrophage Polarization and Its Effects on Intervertebral Disc Degeneration,” The Journal of Physiology 602, no. 7 (2024): 1341–1369.

[333] J. Tu, W. Li, S. Yang, et al., “Single-Cell Transcriptome Profiling Reveals Multicellular Ecosystem of Nucleus Pulposus During Degeneration Progression,” Advanced science (Weinheim) 9, no. 3 (2022): e2103631.

[334] C. Zhang, H. Li, H. Wang, et al., “Identifying Myeloid-Derived Suppressor Cells and Lipocalin-2 as Therapeutic Targets for Intervertebral Disc Degeneration,” Advanced Science (Weinheim) 12, no. 34 (2025): e00505.

[335] H. Zhou, C. Liu, F. Hu, et al., “Increased Levels of Circulating Granulocytic Myeloid‑Derived Suppressor Cells in Lumbar Disc Herniation,” Experimental and Therapeutic Medicine 26, no. 2 (2023): 367.

[336] A. J. Cruz-Jentoft and A. A. Sayer, “Sarcopenia,” Lancet 393, no. 10191 (2019): 2636–2646.

[337] A. A. Sayer, R. Cooper, H. Arai, P. M. Cawthon, M. J. Ntsama Essomba, and R. A. Fielding, “Sarcopenia,” Nature Reviews Disease Primers 10, no. 1 (2024): 68.

[338] X. Zhang, H. Li, M. He, J. Wang, Y. Wu, and Y. Li, “Immune System and Sarcopenia: Presented Relationship and Future Perspective,” Experimental Gerontology 164 (2022): 111823.

[339] S. J. Heo and Y. S. Jee, “Characteristics of Age Classification Into Five-Year Intervals to Explain Sarcopenia and Immune Cells in Older Adults,” Medicina (Kaunas, Lithuania) 59, no. 10 (2023): 1700.

[340] S. Doi, S. Yasuda, M. Miyashita, et al., “Prognostic Relevance of Sarcopenia and Tumor-infiltrating CD8(+) T Cells in Patients With Hepatocellular Carcinoma,” Annals of Gastroenterological Surgery 9, no. 2 (2025): 359–368.

[341] S. Masuda, K. Yamakawa, A. Masuda, et al., “Association of Sarcopenia With a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis,” Annals of Surgical Oncology 30, no. 9 (2023): 5776–5787.

[342] S. L. Ma, J. Wu, L. Zhu, et al., “Peripheral Blood T Cell Gene Expression Responses to Exercise and HMB in Sarcopenia,” Nutrients 13, no. 7 (2021): 2313.

[343] S. W. Huang, T. Xu, C. T. Zhang, and H. L. Zhou, “Relationship of Peripheral Lymphocyte Subsets and Skeletal Muscle Mass Index in Sarcopenia: A Cross-Sectional Study,” Journal of Nutrition, Health and Aging 24, no. 3 (2020): 325–329.

[344] A. Granic, C. Martin-Ruiz, R. M. Dodds, et al., “Immunosenescence Profiles Are Not Associated With Muscle Strength, Physical Performance and Sarcopenia Risk in Very Old Adults: The Newcastle 85+ Study,” Mechanisms of Ageing and Development 190 (2020): 111321.

[345] L. Shen, Y. Zong, J. Zhao, et al., “Characterizing the Skeletal Muscle Immune Microenvironment for Sarcopenia: Insights From Transcriptome Analysis and Histological Validation,” Frontiers in Immunology 15 (2024): 1414387.

[346] H. J. Oh, H. Jin, and B. Y. Lee, “Hesperidin Ameliorates Sarcopenia Through the Regulation of Inflammaging and the AKT/mTOR/FoxO3a Signaling Pathway in 22-26-Month-Old Mice,” Cells 12, no. 15 (2023): 2015.

[347] G. Song, H. J. Oh, H. Jin, H. Han, and B. Y. Lee, “GABA Prevents Sarcopenia by Regulation of Muscle Protein Degradation and Inflammaging in 23- to 25-Month-Old Female Mice,” Journal of Cachexia, Sarcopenia and Muscle 15, no. 6 (2024): 2852–2864.

[348] E. Alcalde-Estevez, A. Moreno-Piedra, A. Asenjo-Bueno, et al., “Aging-related Hyperphosphatemia Triggers the Release of TNF-alpha From Macrophages, Promoting Indicators of Sarcopenia Through the Reduction of IL-15 Expression in Skeletal Muscle,” Life Sciences 368 (2025): 123507.

[349] Y. Y. Chen, T. W. Kao, Y. L. Chiu, T. C. Peng, H. F. Yang, and W. L. Chen, “Association between Interleukin-12 and Sarcopenia,” Journal of Inflammation Research 14 (2021): 2019–2029.

[350] X. Zhang, P. Zhang, Y. Zhu, et al., “Myogenic Nano-adjuvant for Orthopedic-related Sarcopenia via Mitochondrial Homeostasis Modulation in Macrophage-myosatellite Metabolic Crosstalk,” Journal of Nanobiotechnology 23, no. 1 (2025): 390.

[351] Z. Zeng, Z. Zhang, L. Chang, et al., “Therapeutic Silicate Biomaterials for Sarcopenia Treatment by Inhibiting Inflammation and Enhancing Muscle Regeneration Through Regulation of Sarcolipin/SIRT Signaling Pathway,” Bioactive Materials 51 (2025): 787–806.

[352] P. Ding, H. Wu, T. Li, et al., “Impact of Preoperative Sarcopenia on Postoperative Complications and Prognosis in Patients Undergoing Robotic Gastric Cancer Surgery: A Propensity Score Matching Study,” Nutrition (Burbank, Los Angeles County, Calif) 123 (2024): 112408.

[353] L. Xiao, Y. Liu, X. Zhang, et al., “Prognostic Value of Sarcopenia and Inflammatory Indices Synergy in Patients With Esophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy,” BMC cancer 24, no. 1 (2024): 860.

[354] Y. Zhang, L. Zhang, Y. Guan, et al., “Establishment and Validation of a Risk Prediction Model for Sarcopenia in Gastrointestinal Cancer Patients: A Systematic Review and Meta-analysis-based Approach,” Clinical Nutrition 43, no. 11 (2024): 91–98.

[355] I. Balazs, M. Stelzer, J. Traub, A. Horvath, N. Feldbacher, and V. Stadlbauer, “Primary Sarcopenia Is Associated With Elevated Spontaneous NET Formation,” Frontiers in Cell and Developmental Biology 12 (2024): 1347495.

[356] Y. Wang, L. Wang, Y. Zhang, et al., “Comprehensive Profiling of Chemokine and NETosis-associated Genes in Sarcopenia: Construction of a Machine Learning-based Diagnostic Nomogram,” Frontiers in Medicine (Lausanne) 12 (2025): 1606430.

[357] Y. W. Chen, S. He, Y. Wang, L. Y. Hu, Q. K. Chen, and S. Y. Liu, “Mitochondrial Insights: Key Biomarkers and Potential Treatments for Diabetic Nephropathy and Sarcopenia,” Frontiers in Cell and Developmental Biology 13 (2025): 1596204.

[358] Y. He, T. Lin, R. Liang, et al., “Interleukin 25 Promotes Muscle Regeneration in Sarcopenia by Regulating Macrophage-mediated Sonic Hedgehog Signaling,” International Immunopharmacology 139 (2024): 112662.

[359] Y. Liu, M. Ge, X. Xiao, Y. Lu, W. Zhao, and K. Zheng, “Sarcosine Decreases in Sarcopenia and Enhances Muscle Regeneration and Adipose Thermogenesis by Activating Anti-inflammatory Macrophages,” Nature Aging 5, no. 9 (2025): 1810–1827.

[360] M. Hong, I. H. Han, I. Choi, et al., “Magnoliae Cortex Alleviates Muscle Wasting by Modulating M2 Macrophages in a Cisplatin-Induced Sarcopenia Mouse Model,” International Journal of Molecular Sciences 22, no. 6 (2021): 3188.

[361] Y. Wang, S. S. Welc, M. Wehling-Henricks, et al., “Myeloid Cell-specific Mutation of Spi1 Selectively Reduces M2-biased Macrophage Numbers in Skeletal Muscle, Reduces Age-related Muscle Fibrosis and Prevents Sarcopenia,” Aging Cell 21, no. 10 (2022): e13690.

[362] S. Schiaffino, M. G. Pereira, S. Ciciliot, and P. Rovere-Querini, “Regulatory T Cells and Skeletal Muscle Regeneration,” Febs Journal 284, no. 4 (2017): 517–524.

[363] S. Oh, J. Y. Yang, C. H. Park, K. H. Son, and K. Byun, “Dieckol Reduces Muscle Atrophy by Modulating Angiotensin Type II Type 1 Receptor and NADPH Oxidase in Spontaneously Hypertensive Rats,” Antioxidants (Basel) 10, no. 10 (2021): 1561.

[364] Y. Xiang, J. Dai, L. Xu, X. Li, J. Jiang, and J. Xu, “Research Progress in Immune Microenvironment Regulation of Muscle Atrophy Induced by Peripheral Nerve Injury,” Life Sciences 287 (2021): 120117.

[365] A. Narsale, R. Moya, J. Ma, et al., “Cancer-driven Changes Link T Cell Frequency to Muscle Strength in People With Cancer: A Pilot Study,” Journal of Cachexia, Sarcopenia and Muscle 10, no. 4 (2019): 827–843.

[366] J. Yu, H. Ahn, K. Y. Han, et al., “Paradoxical Effect of Myosteatosis on the Immune Checkpoint Inhibitor Response in Metastatic Renal Cell Carcinoma,” Journal of Cachexia, Sarcopenia and Muscle 16, no. 2 (2025): e13758.

[367] A. Traweger, A. Scott, M. Kjaer, et al., “Achilles Tendinopathy,” Nature Reviews Disease Primers 11, no. 1 (2025): 20.

[368] M. T. Cooper, “Common Painful Foot and Ankle Conditions: A Review,” Jama 330, no. 23 (2023): 2285–2294.

[369] M. S. Kragsnaes, U. Fredberg, K. Stribolt, S. G. Kjaer, K. Bendix, and T. Ellingsen, “Stereological Quantification of Immune-competent Cells in Baseline Biopsy Specimens From Achilles Tendons: Results From Patients With Chronic Tendinopathy Followed for More Than 4 Years,” American Journal of Sports Medicine 42, no. 10 (2014): 2435–2445.

[370] N. M. Malmgaard-Clausen, M. Kjaer, and S. G. Dakin, “Pathological Tendon Histology in Early and Chronic Human Patellar Tendinopathy,” Translational Sports Medicine 2022 (2022): 2799665.

[371] N. L. Millar, A. J. Hueber, J. H. Reilly, et al., “Inflammation Is Present in Early human Tendinopathy,” American Journal of Sports Medicine 38, no. 10 (2010): 2085–2091.

[372] N. Cho, S. G. Lee, J. O. Kim, et al., “Identification of Differentially Expressed Genes Associated With Extracellular Matrix Degradation and Inflammatory Regulation in Calcific Tendinopathy Using RNA Sequencing,” Calcified Tissue International 107, no. 5 (2020): 489–498.

[373] Z. Chen, M. Li, P. Chen, et al., “Mechanical Overload-induced Release of Extracellular Mitochondrial Particles From Tendon Cells Leads to Inflammation in Tendinopathy,” Experimental & Molecular Medicine 56, no. 3 (2024): 583–599.

[374] J. Xu, M. Zheng, Z. Feng, and Q. Lin, “CCL4L2 participates in Tendinopathy Progression by Promoting Macrophage Inflammatory Responses: A Single-cell Analysis,” Journal of Orthopaedic Surgery and Research 19, no. 1 (2024): 836.

[375] J. Herman, B. Le Goff, J. De Lima, R. Brion, C. Chevalier, and F. Blanchard, “Pro-inflammatory Effects of human Apatite Crystals Extracted From Patients Suffering From Calcific Tendinopathy,” Arthritis Research & Therapy 23, no. 1 (2021): 131.

[376] N. L. Millar, M. Akbar, A. L. Campbell, et al., “IL-17A Mediates Inflammatory and Tissue Remodelling Events in Early human Tendinopathy,” Scientific Reports 6 (2016): 27149.

[377] H. Jiang, Y. Xie, J. Lu, et al., “Pristimerin Suppresses AIM2 Inflammasome by Modulating AIM2-PYCARD/ASC Stability via Selective Autophagy to Alleviate Tendinopathy,” Autophagy 20, no. 1 (2024): 76–93.

[378] J. Christensen, H. Alfredson, and G. Andersson, “Protease-activated Receptors in the Achilles Tendon-a Potential Explanation for the Excessive Pain Signalling in Tendinopathy,” Molecular Pain 11 (2015): 13.

[379] R. Gao, T. Ye, Z. Zhu, et al., “Small Extracellular Vesicles From iPSC-derived Mesenchymal Stem Cells Ameliorate Tendinopathy Pain by Inhibiting Mast Cell Activation,” Nanomedicine (London) 17, no. 8 (2022): 513–529.

[380] H. Behzad, A. Sharma, R. Mousavizadeh, A. Lu, and A. Scott, “Mast Cells Exert Pro-inflammatory Effects of Relevance to the Pathophyisology of Tendinopathy,” Arthritis Research & Therapy 15, no. 6 (2013): R184.

[381] Y. Wang, J. Zhang, Y. Lin, et al., “A Global Phosphorylation Atlas of Proteins within Pathological Site of Rotator Cuff Tendinopathy,” Frontiers in Molecular Biosciences 8 (2021): 787008.

[382] Y. T. Wu, Y. T. Wu, T. C. Huang, F. C. Su, I. M. Jou, and C. C. Wu, “Sequential Inflammation Model for Achilles Tendinopathy by Elastin Degradation With Treadmill Exercise,” Journal of Orthopaedic Translation 23 (2020): 113–121.

[383] D. Kouroupis, C. Perucca Orfei, D. Correa, G. Talo, F. Libonati, and P. De Luca, “Cellular and Structural Changes in Achilles and Patellar Tendinopathies: A Pilot in Vivo Study,” Biomedicines 12, no. 5 (2024): 995.

[384] W. Fu, R. Yang, and J. Li, “Single-cell and Spatial Transcriptomics Reveal Changes in Cell Heterogeneity During Progression of human Tendinopathy,” BMC Biology 21, no. 1 (2023): 132.

[385] R. Chen, L. Ai, J. Zhang, and D. Jiang, “Dendritic Cell-Derived Exosomes Promote Tendon Healing and Regulate Macrophage Polarization in Preventing Tendinopathy,” International Journal of Nanomedicine 19 (2024): 11701–11718.

[386] C. Wang, Y. Zhang, G. Zhang, W. Yu, and Y. He, “Adipose Stem Cell-Derived Exosomes Ameliorate Chronic Rotator Cuff Tendinopathy by Regulating Macrophage Polarization: From a Mouse Model to a Study in Human Tissue,” American Journal of Sports Medicine 49, no. 9 (2021): 2321–2331.

[387] G. Wu, Q. Su, J. Li, et al., “NAMPT Encapsulated by Extracellular Vesicles From Young Adipose-derived Mesenchymal Stem Cells Treated Tendinopathy in a "One-Stone-Two-Birds" Manner,” Journal of Nanobiotechnology 21, no. 1 (2023): 7.

[388] T. Ye, Z. Chen, J. Zhang, et al., “Large Extracellular Vesicles Secreted by human iPSC-derived MSCs Ameliorate Tendinopathy via Regulating Macrophage Heterogeneity,” Bioactive Materials 21 (2023): 194–208.

[389] D. Li, S. Li, S. He, et al., “Restoring Tendon Microenvironment in Tendinopathy: Macrophage Modulation and Tendon Regeneration With Injectable Tendon Hydrogel and Tendon-derived Stem Cells Exosomes,” Bioactive Materials 47 (2025): 152–169.

[390] S. Lopez-Cerda, G. Molinaro, R. P. Tello, et al., “Study of the Synergistic Immunomodulatory and Antifibrotic Effects of Dual-Loaded Budesonide and Serpine1 siRNA Lipid-Polymer Nanoparticles Targeting Macrophage Dysregulation in Tendinopathy,” ACS Applied Materials and Interfaces 16, no. 15 (2024): 18643–18657.

[391] J. Espejo Valle-Inclan, S. De Noon, K. Trevers, H. Elrick, I. van Belzen, and S. Zumalave, “Ongoing Chromothripsis Underpins Osteosarcoma Genome Complexity and Clonal Evolution,” Cell 188, no. 2 (2025): 352–730. e22.

[392] J. Shan, Z. Lin, H. Rashid, et al., “A Novel Therapeutic Strategy for Osteosarcoma Using Anti-GD2 ADC and EZH2 Inhibitor,” Biomarker Research 13, no. 1 (2025): 87.

[393] S. Yu and X. Yao, “Advances on Immunotherapy for Osteosarcoma,” Molecular Cancer 23, no. 1 (2024): 192.

[394] B. Li, Z. Wang, H. Wu, et al., “Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma,” Cancer Research 78, no. 14 (2018): 3938–3953.

[395] R. Ji, Y. Wang, D. Pan, et al., “NUCB2 inhibition Antagonizes Osteosarcoma Progression and Promotes Anti-tumor Immunity Through Inactivating NUCKS1/CXCL8 Axis,” Cancer Letters 591 (2024): 216893.

[396] K. Jiang, Q. Zhang, Y. Fan, et al., “MYC Inhibition Reprograms Tumor Immune Microenvironment by Recruiting T Lymphocytes and Activating the CD40/CD40L System in Osteosarcoma,” Cell Death Discovery 8, no. 1 (2022): 117.

[397] K. Yahiro, Y. Matsumoto, H. Yamada, et al., “Activation of TLR4 Signaling Inhibits Progression of Osteosarcoma by Stimulating CD8-positive Cytotoxic Lymphocytes,” Cancer Immunology, Immunotherapy 69, no. 5 (2020): 745–758.

[398] L. Fernandez, J. Y. Metais, A. Escudero, et al., “Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells,” Clinical Cancer Research 23, no. 19 (2017): 5824–5835.

[399] Y. Jin, Z. Jia, X. Xia, et al., “Anti-CD137 Agonist Antibody-independent and Clinically Feasible Preparation of Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma and Osteosarcoma,” Frontiers in Immunology 16 (2025): 1557006.

[400] M. Liu, L. L. Sun, Y. J. Li, et al., “Trastuzumab Enhanced the Cytotoxicity of Vgamma9Vdelta2 T Cells Against Zoledronate-sensitized Osteosarcoma Cells,” International Immunopharmacology 28, no. 1 (2015): 160–167.

[401] Y. Wang, X. Wang, Y. Liu, et al., “A Novel Hypoxia- and Lactate Metabolism-related Prognostic Signature to Characterize the Immune Landscape and Predict Immunotherapy Response in Osteosarcoma,” Frontiers in Immunology 15 (2024): 1467052.

[402] Z. Zhang, W. Ji, J. Huang, Y. Zhang, Y. Zhou, and J. Zhang, “Characterization of the Tumour Microenvironment Phenotypes in Malignant Tissues and Pleural Effusion From Advanced Osteoblastic Osteosarcoma Patients,” Clinical and Translational Medicine 12, no. 11 (2022): e1072.

[403] Z. Wang, Z. Wang, B. Li, S. Wang, T. Chen, and Z. Ye, “Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma,” Frontiers in Immunology 10 (2019): 1114.

[404] H. Gassmann, M. Thiede, J. Weiss, et al., “Cytokine Screening Identifies TNF to Potentially Enhance Immunogenicity of Pediatric Sarcomas,” Frontiers in Immunology 15 (2024): 1347404.

[405] Y. Ogiwara, M. Nakagawa, F. Nakatani, Y. Uemura, R. Zhang, and C. Kudo-Saito, “Blocking FSTL1 Boosts NK Immunity in Treatment of Osteosarcoma,” Cancer Letters 537 (2022): 215690.

[406] M. M. Cho, L. Song, A. E. Quamine, et al., “CD155 blockade Enhances Allogeneic Natural Killer Cell-mediated Antitumor Response Against Osteosarcoma,” Journal for ImmunoTherapy of Cancer 13, no. 4 (2025): e008755.

[407] Y. Zhou, D. Yang, Q. Yang, et al., “Single-cell RNA Landscape of Intratumoral Heterogeneity and Immunosuppressive Microenvironment in Advanced Osteosarcoma,” Nature Communications 11, no. 1 (2020): 6322.

[408] W. Liu, H. Hu, Z. Shao, et al., “Characterizing the Tumor Microenvironment at the Single-cell Level Reveals a Novel Immune Evasion Mechanism in Osteosarcoma,” Bone Research 11, no. 1 (2023): 4.

[409] A. M. Taylor, J. Sheng, P. K. S. Ng, et al., “Immunosuppressive Tumor Microenvironment of Osteosarcoma,” Cancers (Basel) 17, no. 13 (2025): 2117.

[410] A. J. Gentles, S. V. Bratman, L. J. Lee, et al., “Integrating Tumor and Stromal Gene Expression Signatures with Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer,” JNCI: Journal of the National Cancer Institute 107, no. 10 (2015): djv211.

[411] Q. Huang, X. Liang, T. Ren, et al., “The Role of Tumor-associated Macrophages in Osteosarcoma Progression—therapeutic Implications,” Cellular Oncology (Dordrecht) 44, no. 3 (2021): 525–539.

[412] M. D. Thakur, C. J. Franz, L. Brennan, et al., “Immune Contexture of Paediatric Cancers,” European Journal of Cancer 170 (2022): 179–193.

[413] C. Dumars, J. M. Ngyuen, A. Gaultier, et al., “Dysregulation of Macrophage Polarization Is Associated With the Metastatic Process in Osteosarcoma,” Oncotarget 7, no. 48 (2016): 78343–78354.

[414] W. Liu, Q. Long, W. Zhang, et al., “miRNA-221-3p Derived From M2-polarized Tumor-associated Macrophage Exosomes Aggravates the Growth and Metastasis of Osteosarcoma Through SOCS3/JAK2/STAT3 Axis,” Aging (Albany NY) 13, no. 15 (2021): 19760–19775.

[415] Y. Kimura and M. Sumiyoshi, “Anti-tumor and Anti-metastatic Actions of Wogonin Isolated From Scutellaria baicalensis Roots Through Anti-lymphangiogenesis,” Phytomedicine 20, no. 3-4 (2013): 328–336.

[416] J. A. Ligon, W. Choi, G. Cojocaru, et al., “Pathways of Immune Exclusion in Metastatic Osteosarcoma Are Associated With Inferior Patient Outcomes,” Journal for ImmunoTherapy of Cancer 9, no. 5 (2021): e001772.

[417] F. He, G. Ding, W. Jiang, X. Fan, and L. Zhu, “Effect of Tumor-associated Macrophages on lncRNA PURPL/miR-363/PDZD2 Axis in Osteosarcoma Cells,” Cell Death Discovery 7, no. 1 (2021): 307.

[418] J. Y. He, F. Y. Huo, H. C. Tang, B. Liu, and L. L. Bu, “Myeloid-derived Suppressor Cells in Head and Neck Squamous Cell Carcinoma,” International Review of Cell and Molecular Biology 375 (2023): 33–92.

[419] E. Shokati and E. Safari, “The Immunomodulatory Role of Exosomal microRNA Networks in the Crosstalk Between Tumor-associated Myeloid-derived Suppressor Cells and Tumor Cells,” International Immunopharmacology 120 (2023): 110267.

[420] S. Wang, X. Zhao, S. Wu, D. Cui, and Z. Xu, “Myeloid-derived Suppressor Cells: Key Immunosuppressive Regulators and Therapeutic Targets in Hematological Malignancies,” Biomarker Research 11, no. 1 (2023): 34.

[421] K. Jiang, J. Li, J. Zhang, et al., “SDF-1/CXCR4 Axis Facilitates Myeloid-derived Suppressor Cells Accumulation in Osteosarcoma Microenvironment and Blunts the Response to anti-PD-1 Therapy,” International Immunopharmacology 75 (2019): 105818.

[422] Y. Guan, R. Zhang, Z. Peng, D. Dong, G. Wei, and Y. Wang, “Inhibition of IL-18-mediated Myeloid Derived Suppressor Cell Accumulation Enhances Anti-PD1 Efficacy Against Osteosarcoma Cancer,” Journal of Bone Oncology 9 (2017): 59–64.

[423] X. Shi, X. Li, H. Wang, Z. Yu, Y. Zhu, and Y. Gao, “Specific Inhibition of PI3Kdelta/Gamma Enhances the Efficacy of Anti-PD1 Against Osteosarcoma Cancer,” Journal of Bone Oncology 16 (2019): 100206.

[424] D. T. Ammons, R. A. Harris, L. S. Hopkins, J. Kurihara, K. Weishaar, and S. Dow, “A Single-cell RNA Sequencing Atlas of Circulating Leukocytes From Healthy and Osteosarcoma Affected Dogs,” Frontiers in Immunology 14 (2023): 1162700.

[425] C. Deng, Y. Xu, J. Fu, et al., “Reprograming the Tumor Immunologic Microenvironment Using Neoadjuvant Chemotherapy in Osteosarcoma,” Cancer Science 111, no. 6 (2020): 1899–1909.

[426] M. Kansara, K. Thomson, P. Pang, et al., “Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23,” Cancer Discovery 9, no. 11 (2019): 1511–1519.

[427] B. J. Biller, A. Guth, J. H. Burton, and S. W. Dow, “Decreased Ratio of CD8+ T Cells to Regulatory T Cells Associated With Decreased Survival in Dogs With Osteosarcoma,” Journal of Veterinary Internal Medicine 24, no. 5 (2010): 1118–1123.

[428] B. Fritzsching, J. Fellenberg, L. Moskovszky, et al., “CD8(+)/FOXP3(+)-ratio in Osteosarcoma Microenvironment Separates Survivors From Non-survivors: A Multicenter Validated Retrospective Study,” Oncoimmunology 4, no. 3 (2015): e990800.

[429] M. Yang, H. Zheng, K. Xu, et al., “A Novel Signature to Guide Osteosarcoma Prognosis and Immune Microenvironment: Cuproptosis-related lncRNA,” Frontiers in Immunology 13 (2022): 919231.

[430] M. X. Liu, Q. Y. Liu, Y. Liu, et al., “Interleukin-35 Suppresses Antitumor Activity of Circulating CD8(+) T Cells in Osteosarcoma Patients,” Connective Tissue Research 60, no. 4 (2019): 367–375.

[431] X. Li, Y. Chen, X. Liu, et al., “Tim3/Gal9 interactions Between T Cells and Monocytes Result in an Immunosuppressive Feedback Loop That Inhibits Th1 Responses in Osteosarcoma Patients,” International Immunopharmacology 44 (2017): 153–159.

[432] Y. Takahashi, T. Yasui, K. Tamari, et al., “Radiation Enhanced the Local and Distant Anti-tumor Efficacy in Dual Immune Checkpoint Blockade Therapy in Osteosarcoma,” PLoS ONE 12, no. 12 (2017): e0189697.

[433] K. Yoshida, M. Okamoto, J. Sasaki, et al., “Anti-PD-1 Antibody Decreases Tumour-infiltrating Regulatory T Cells,” BMC Cancer 20, no. 1 (2020): 25.

[434] E. Kozawa, H. Sugiura, J. Wasa, et al., “Suppression of Tumour Metastasis in a Murine Osteosarcoma Model With Anti-CD25 Monoclonal Antibody Treatment,” Anticancer Research 30, no. 12 (2010): 5019–5022.

[435] J. Zhang, Y. Li, S. Yang, L. Zhang, and W. Wang, “Anti-CD40 mAb Enhanced Efficacy of Anti-PD1 Against Osteosarcoma,” Journal of Bone Oncology 17 (2019): 100245.

[436] D. Lavie, A. Ben-Shmuel, N. Erez, and R. Scherz-Shouval, “Cancer-associated Fibroblasts in the Single-cell Era,” Nature Cancer 3, no. 7 (2022): 793–807.

[437] G. Biffi and D. A. Tuveson, “Diversity and Biology of Cancer-Associated Fibroblasts,” Physiological Reviews 101, no. 1 (2021): 147–176.

[438] X. Mao, J. Xu, W. Wang, et al., “Crosstalk Between Cancer-associated Fibroblasts and Immune Cells in the Tumor Microenvironment: New Findings and Future Perspectives,” Molecular Cancer 20, no. 1 (2021): 131.

[439] A. Obradovic, D. Graves, M. Korrer, et al., “Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer,” Clinical Cancer Research 28, no. 10 (2022): 2094–2109.

[440] B. C. Ozdemir, T. Pentcheva-Hoang, J. L. Carstens, et al., “Depletion of Carcinoma-associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer With Reduced Survival,” Cancer Cell 25, no. 6 (2014): 719–734.

[441] Y. Zhang, Z. Liu, X. Yang, et al., “H3K27 acetylation Activated-COL6A1 Promotes Osteosarcoma Lung Metastasis by Repressing STAT1 and Activating Pulmonary Cancer-associated Fibroblasts,” Theranostics 11, no. 3 (2021): 1473–1492.

[442] A. Mazumdar, J. Urdinez, A. Boro, et al., “Osteosarcoma-Derived Extracellular Vesicles Induce Lung Fibroblast Reprogramming,” International Journal of Molecular Sciences 21, no. 15 (2020): 5451.

[443] L. Lin, K. Huang, W. Guo, C. Zhou, G. Wang, and Q. Zhao, “Conditioned Medium of the Osteosarcoma Cell Line U2OS Induces hBMSCs to Exhibit Characteristics of Carcinoma-associated Fibroblasts via Activation of IL-6/STAT3 Signalling,” Journal of Biochemistry 168, no. 3 (2020): 265–271.

[444] X. Chang, Q. Tan, J. Xu, et al., “Tumor-derived Exosomal linc00881 Induces Lung Fibroblast Activation and Promotes Osteosarcoma Lung Migration,” Cancer Cell International 23, no. 1 (2023): 287.

[445] Y. Xu, P. Chen, D. Liu, Q. Xu, H. Meng, and X. Wang, “Exploration of s New Biomarker in Osteosarcoma and Association With Clinical Outcomes: (TOP2A+) Cancer Associated Fibroblasts,” The Journal of Gene Medicine 25, no. 11 (2023): e3528.

[446] S. Jaillon, A. Ponzetta, D. Di Mitri, A. Santoni, R. Bonecchi, and A. Mantovani, “Neutrophil Diversity and Plasticity in Tumour Progression and Therapy,” Nature Reviews Cancer 20, no. 9 (2020): 485–503.

[447] A. Mantovani, “The Yin-yang of Tumor-associated Neutrophils,” Cancer Cell 16, no. 3 (2009): 173–174.

[448] H. Que, Q. Fu, T. Lan, X. Tian, and X. Wei, “Tumor-associated Neutrophils and Neutrophil-targeted Cancer Therapies,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877, no. 5 (2022): 188762.

[449] R. Sun, J. Luo, D. Li, et al., “Neutrophils With Protumor Potential Could Efficiently Suppress Tumor Growth After Cytokine Priming and in Presence of Normal NK Cells,” Oncotarget 5, no. 24 (2014): 12621–12634.

[450] S. Tan and R. Chao, “An Exploration of Osteosarcoma Metastasis Diagnostic Markers Based on Tumor-Associated Neutrophils,” Discovery Medicine 35, no. 176 (2023): 300–311.

[451] W. D. Tap, G. M. Cote, H. Burris, et al., “Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients With Conventional Chondrosarcoma,” Clinical Cancer Research 31, no. 11 (2025): 2108–2114.

[452] B. Li, G. Li, X. Yan, et al., “Fresh Tissue Multi-omics Profiling Reveals Immune Classification and Suggests Immunotherapy Candidates for Conventional Chondrosarcoma,” Clinical Cancer Research 27, no. 23 (2021): 6543–6558.

[453] F. A. Simard, I. Richert, A. Vandermoeten, et al., “Description of the Immune Microenvironment of Chondrosarcoma and Contribution to Progression,” Oncoimmunology 6, no. 2 (2017): e1265716.

[454] M. Minopoli, S. Sarno, G. Di Carluccio, et al., “Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma,” Cells 9, no. 4 (2020): 1062.

[455] R. Iseulys, G. B. Anne, B. Corinne, D. B. P. Gonzague, K. Marie, and B. Jean-Yves, “The Immune Landscape of Chondrosarcoma Reveals an Immunosuppressive Environment in the Dedifferentiated Subtypes and Exposes CSFR1+ Macrophages as a Promising Therapeutic Target,” Journal of Bone Oncology 20 (2020): 100271.

[456] M. Kostine, A. H. Cleven, N. F. de Miranda, A. Italiano, A. M. Cleton-Jansen, and J. V. Bovee, “Analysis of PD-L1, T-cell Infiltrate and HLA Expression in Chondrosarcoma Indicates Potential for Response to Immunotherapy Specifically in the Dedifferentiated Subtype,” Modern Pathology 29, no. 9 (2016): 1028–1037.

[457] C. Li, W. Wang, B. Zhong, et al., “Long Noncoding RNA TUG1 Promotes Chondrosarcoma Progression and M2 Polarization,” Genes & Diseases 12, no. 4 (2025): 101474.

[458] R. Quoniou, E. Moreau, F. Cachin, et al., “Chondrosarcoma Co-Culture 3D Model Horizontal Line an Insight to Evaluate Drugs Acting on TAMs,” ACS Biomaterials Science & Engineering 10, no. 9 (2024): 5832–5843.

[459] Y. Wen, Y. Li, S. Cheng, et al., “Partition-Less Digital Immunoassay Using Configurable Topographic Nanoarrays for Extracellular Vesicle Diagnosis of Ewing Sarcoma,” ACS Nano 19, no. 12 (2025): 11973–11986.

[460] E. D. Wrenn, A. A. Apfelbaum, E. R. Rudzinski, et al., “Cancer-Associated Fibroblast-Like Tumor Cells Remodel the Ewing Sarcoma Tumor Microenvironment,” Clinical Cancer Research 29, no. 24 (2023): 5140–5154.

[461] E. Morales, M. Olson, F. Iglesias, S. Dahiya, T. Luetkens, and D. Atanackovic, “Role of Immunotherapy in Ewing Sarcoma,” Journal for ImmunoTherapy of Cancer 8, no. 2 (2020): e000653.

[462] D. Berghuis, A. S. de Hooge, S. J. Santos, et al., “Reduced human Leukocyte Antigen Expression in Advanced-stage Ewing Sarcoma: Implications for Immune Recognition,” Journal of Pathology 218, no. 2 (2009): 222–231.

[463] I. C. Henrich, K. Jain, R. Young, et al., “Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma Through Immune Activation,” Cancer Research 81, no. 8 (2021): 2171–2183.

[464] W. Luo, H. Hoang, H. Zhu, et al., “Circumventing Resistance Within the Ewing Sarcoma Microenvironment by Combinatorial Innate Immunotherapy,” Journal for ImmunoTherapy of Cancer 12, no. 9 (2024): e009726.

[465] H. Zhang, I. Maric, M. J. DiPrima, et al., “Fibrocytes Represent a Novel MDSC Subset Circulating in Patients With Metastatic Cancer,” Blood 122, no. 7 (2013): 1105–1113.

[466] N. L. Denton, C. Y. Chen, B. Hutzen, et al., “Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment,” Molecular Therapy Oncolytics 11 (2018): 62–74.

[467] P. Brinkrolf, S. Landmeier, B. Altvater, et al., “A High Proportion of Bone Marrow T Cells With Regulatory Phenotype (CD4+CD25hiFoxP3+) in Ewing Sarcoma Patients Is Associated With Metastatic Disease,” International Journal of Cancer 125, no. 4 (2009): 879–886.

[468] T. V. Tilak, S. Sharawat, R. Gupta, S. Agarwala, S. Vishnubhatla, and S. Bakhshi, “Circulating T-regulatory Cells in PNET: A Prospective Study,” Pediatric Blood & Cancer 61, no. 2 (2014): 228–232.

[469] S. J. Schober, C. Schoening, J. Eck, et al., “The Oncolytic Adenovirus XVir-N-31 Joins Forces With CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma,” Clinical Cancer Research 29, no. 10 (2023): 1996–2011.

[470] P. Sargos, M. P. Sunyach, A. Ducassou, et al., “Results of a Phase Ib Study of olaparib With Concomitant Radiotherapy in Soft-tissue Sarcoma: A French Sarcoma Group Study,” Annals of Oncology 36, no. 5 (2025): 592–600.

[471] E. Jumaniyazova, A. Lokhonina, D. Dzhalilova, A. Kosyreva, and T. Fatkhudinov, “Immune Cells in the Tumor Microenvironment of Soft Tissue Sarcomas,” Cancers (Basel) 15, no. 24 (2023): 5760.

[472] D. S. Moura, J. M. Lopez-Marti, I. Benesova, et al., “Predictive and Dynamic Signature for Antiangiogenics in Combination With a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial,” Clinical Cancer Research 30, no. 22 (2024): 5192–5206.

[473] B. A. Schroeder, N. A. LaFranzo, B. J. LaFleur, et al., “CD4+ T Cell and M2 Macrophage Infiltration Predict Dedifferentiated Liposarcoma Patient Outcomes,” Journal for ImmunoTherapy of Cancer 9, no. 8 (2021): e002812.

[474] N. Matsuda, H. Yamamoto, T. Habu, et al., “Prognostic Impact of Tumor-Infiltrating Lymphocytes, Tertiary Lymphoid Structures, and Neutrophil-to-Lymphocyte Ratio in Pulmonary Metastases From Uterine Leiomyosarcoma,” Annals of Surgical Oncology 30, no. 13 (2023): 8727–8734.

[475] Y. Klaver, M. Rijnders, A. Oostvogels, et al., “Differential Quantities of Immune Checkpoint-expressing CD8 T Cells in Soft Tissue Sarcoma Subtypes,” Journal for ImmunoTherapy of Cancer 8, no. 2 (2020): e000271.

[476] S. van Oost, D. M. Meijer, Z. B. Erdem, et al., “Divergent Therapeutic and Prognostic Impacts of Immunogenic Features in Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma,” Cancer Immunology, Immunotherapy 74, no. 8 (2025): 258.

[477] K. M. Campbell, M. Thaker, E. Medina, et al., “Spatial Profiling Reveals Association Between WNT Pathway Activation and T-cell Exclusion in Acquired Resistance of Synovial Sarcoma to NY-ESO-1 Transgenic T-cell Therapy,” Journal for ImmunoTherapy of Cancer 10, no. 3 (2022): e004190.

[478] A. M. Fuller, H. C. Pruitt, Y. Liu, et al., “Oncogene-induced Matrix Reorganization Controls CD8+ T Cell Function in the Soft-tissue Sarcoma Microenvironment,” Journal of Clinical Investigation 134, no. 11 (2024): e167826.

[479] M. Kanahori, E. Shimada, Y. Matsumoto, et al., “Immune Evasion in Lung Metastasis of Leiomyosarcoma: Upregulation of EPCAM Inhibits CD8(+) T Cell Infiltration,” British Journal of Cancer 130, no. 7 (2024): 1083–1095.

[480] W. De Wispelaere, D. Annibali, S. Tuyaerts, et al., “PI3K/mTOR Inhibition Induces Tumour Microenvironment Remodelling and Sensitises pS6(high) Uterine Leiomyosarcoma to PD-1 Blockade,” Clinical and Translational Medicine 14, no. 5 (2024): e1655.

[481] J. Yang, X. Lu, Q. Cai, et al., “Loss of TACC2 Impairs Chemokine CCL3 and CCL4 Expression and Reduces Response to anti-PD-1 Therapy in Soft Tissue Sarcoma,” Molecular Cancer 24, no. 1 (2025): 158.

[482] H. G. Smith, K. Jamal, J. H. Dayal, et al., “RIPK1-mediated Immunogenic Cell Death Promotes Anti-tumour Immunity Against Soft-tissue Sarcoma,” EMBO Molecular Medicine 12, no. 6 (2020): e10979.

[483] L. Rupp, A. Resag, V. Potkrajcic, et al., “Prognostic Impact of the Post-treatment T Cell Composition and Spatial Organization in Soft Tissue Sarcoma Patients Treated With Neoadjuvant Hyperthermic Radio(chemo)Therapy,” Frontiers in Immunology 14 (2023): 1185197.

[484] J. S. Almeida, L. M. Sousa, P. Couceiro, et al., “Peripheral Immune Profiling of Soft Tissue Sarcoma: Perspectives for Disease Monitoring,” Frontiers in Immunology 15 (2024): 1391840.

[485] L. M. Sousa, J. S. Almeida, T. Fortes-Andrade, et al., “Comprehensive Receptor Repertoire and Functional Analysis of Peripheral NK Cells in Soft Tissue Sarcoma Patients,” Cancers (Basel) 17, no. 15 (2025): 2508.

[486] S. Y. Neo, L. Tong, J. Chong, et al., “Tumor-associated NK Cells Drive MDSC-mediated Tumor Immune Tolerance Through the IL-6/STAT3 Axis,” Science Translational Medicine 16, no. 747 (2024): eadi2952.

[487] S. M. Cruz, C. J. Sholevar, S. J. Judge, et al., “Intratumoral NKp46(+) Natural Killer Cells Are Spatially Distanced From T and MHC-I(+) Cells With Prognostic Implications in Soft Tissue Sarcoma,” Frontiers in Immunology 14 (2023): 1230534.

[488] P. Taborska, P. Lukac, D. Stakheev, et al., “Novel PD-L1- and Collagen-expressing Patient-derived Cell Line of Undifferentiated Pleomorphic Sarcoma (JBT19) as a Model for Cancer Immunotherapy,” Scientific Reports 13, no. 1 (2023): 19079.

[489] Y. Murayama, Y. Kasahara, N. Kubo, et al., “NKp44-based Chimeric Antigen Receptor Effectively Redirects Primary T Cells Against Synovial Sarcoma,” Translational Oncology 25 (2022): 101521.

[490] B. Choi, J. S. Lee, S. J. Kim, D. Hong, J. B. Park, and K. Y. Lee, “Anti-tumor Effects of Anti-PD-1 Antibody, Pembrolizumab, in Humanized NSG PDX Mice Xenografted With Dedifferentiated Liposarcoma,” Cancer Letters 478 (2020): 56–69.

[491] X. Lu, M. Liu, J. Yang, Y. Que, and X. Zhang, “Panobinostat Enhances NK Cell Cytotoxicity in Soft Tissue Sarcoma,” Clinical and Experimental Immunology 209, no. 2 (2022): 127–139.

[492] L. Yan, Z. Wang, C. Cui, et al., “Comprehensive Immune Characterization and T-cell Receptor Repertoire Heterogeneity of Retroperitoneal Liposarcoma,” Cancer Science 110, no. 10 (2019): 3038–3048.

[493] G. Avallone, E. Brigandi, C. Tugnoli, A. Rigillo, B. Bacci, and P. Roccabianca, “Tumor-infiltrating Lymphocytes Vary in Different Canine Soft Tissue Sarcoma Histological Types,” Veterinary Pathology 62, no. 3 (2025): 276–283.

[494] M. A. Smolle, L. Herbsthofer, M. Goda, et al., “Influence of Tumor-infiltrating Immune Cells on Local Control Rate, Distant Metastasis, and Survival in Patients With Soft Tissue Sarcoma,” Oncoimmunology 10, no. 1 (2021): 1896658.

[495] P. Tsagozis, M. Augsten, Y. Zhang, et al., “An Immunosuppressive Macrophage Profile Attenuates the Prognostic Impact of CD20-positive B Cells in human Soft Tissue Sarcoma,” Cancer Immunology, Immunotherapy 68, no. 6 (2019): 927–936.

[496] J. Y. Hong, H. J. Cho, K. H. Yun, et al., “Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response,” Cancer Research and Treatment: Official Journal of Korean Cancer Association 55, no. 2 (2023): 671–683.

[497] C. L. Roland, E. F. Nassif Haddad, E. Z. Keung, W. L. Wang, A. J. Lazar, and H. Lin, “A Randomized, Non-comparative Phase 2 Study of Neoadjuvant Immune-checkpoint Blockade in Retroperitoneal Dedifferentiated Liposarcoma and Extremity/Truncal Undifferentiated Pleomorphic Sarcoma,” Nature Cancer 5, no. 4 (2024): 625–641.

[498] A. Salawu, B. X. Wang, M. Han, et al., “Safety, Immunologic, and Clinical Activity of Durvalumab in Combination With Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial,” Clinical Cancer Research 29, no. 20 (2023): 4128–4138.

[499] Y. Que, W. Xiao, Y. X. Guan, Y. Liang, S. M. Yan, and H. Y. Chen, “PD-L1 Expression Is Associated With FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis,” Journal of Cancer 8, no. 11 (2017): 2018–2025.

[500] M. A. Smolle, L. Herbsthofer, B. Granegger, et al., “T-regulatory Cells Predict Clinical Outcome in Soft Tissue Sarcoma Patients: A Clinico-pathological Study,” British Journal of Cancer 125, no. 5 (2021): 717–724.

[501] H. Chen, Y. Chen, H. Liu, Y. Que, X. Zhang, and F. Zheng, “Integrated Expression Profiles Analysis Reveals Correlations between the IL-33/ST2 Axis and CD8(+) T Cells, Regulatory T Cells, and Myeloid-Derived Suppressor Cells in Soft Tissue Sarcoma,” Frontiers in Immunology 9 (2018): 1179.

[502] M. Spalato-Ceruso, F. Bouteiller, J. P. Guegan, et al., “Pembrolizumab Combined With Low-dose Cyclophosphamide and Intra-tumoral Injection of the Toll-Like Receptor 4 Agonist G100 in Patients With Advanced Pretreated Soft Tissue Sarcoma: Results From the PEMBROSARC Basket Study,” Journal of Hematology & Oncology 15, no. 1 (2022): 157.

[503] Y. Kim, E. Kobayashi, Y. Suehara, et al., “Immunological Status of Peripheral Blood Is Associated With Prognosis in Patients With Bone and Soft-tissue Sarcoma,” Oncology Letters 21, no. 3 (2021): 212.

[504] S. E. Finkelstein, C. Iclozan, M. M. Bui, et al., “Combination of External Beam Radiotherapy (EBRT) With Intratumoral Injection of Dendritic Cells as Neo-adjuvant Treatment of High-risk Soft Tissue Sarcoma Patients,” International Journal of Radiation and Oncology in Biology and Physics 82, no. 2 (2012): 924–932.

[505] A. Levy, D. Morel, M. Texier, et al., “Monocyte-lineage Tumor Infiltration Predicts Immunoradiotherapy Response in Advanced Pretreated Soft-tissue Sarcoma: Phase 2 Trial Results,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 103.

[506] N. Oike, H. Kawashima, A. Ogose, et al., “Prognostic Impact of the Tumor Immune Microenvironment in Synovial Sarcoma,” Cancer Science 109, no. 10 (2018): 3043–3054.

[507] M. Minopoli, S. Sarno, L. Cannella, et al., “Crosstalk Between Macrophages and Myxoid Liposarcoma Cells Increases Spreading and Invasiveness of Tumor Cells,” Cancers (Basel) 13, no. 13 (2021): 3298.

[508] K. R. Patel, A. Martinez, J. M. Stahl, et al., “Increase in PD-L1 Expression After Pre-operative Radiotherapy for Soft Tissue Sarcoma,” Oncoimmunology 7, no. 7 (2018): e1442168.

[509] K. M. Skubitz, J. D. Wilson, E. Y. Cheng, B. R. Lindgren, K. L. M. Boylan, and A. P. N. Skubitz, “Effect of Chemotherapy on Cancer Stem Cells and Tumor-associated Macrophages in a Prospective Study of Preoperative Chemotherapy in Soft Tissue Sarcoma,” Journal of Translational Medicine 17, no. 1 (2019): 130.

[510] F. H. G. Tessaro, E. Y. Ko, M. De Simone, et al., “Single-cell RNA-seq of a Soft-tissue Sarcoma Model Reveals the Critical Role of Tumor-expressed MIF in Shaping Macrophage Heterogeneity,” Cell Reports 39, no. 12 (2022): 110977.

[511] J. J. Barrott, L. A. Kafchinski, H. Jin, et al., “Modeling Synovial Sarcoma Metastasis in the Mouse: PI3'-lipid Signaling and Inflammation,” Journal of Experimental Medicine 213, no. 13 (2016): 2989–3005.

[512] L. Casadei, F. Calore, C. J. Creighton, et al., “Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression,” Cancer Research 77, no. 14 (2017): 3846–3856.

[513] I. Benesova, L. Capkova, A. Ozaniak, et al., “A Comprehensive Analysis of CD47 Expression in Various Histological Subtypes of Soft Tissue Sarcoma: Exploring Novel Opportunities for Macrophage-directed Treatments,” Journal of Cancer Research and Clinical Oncology 150, no. 3 (2024): 134.

[514] S. Ishihara, T. Iwasaki, K. Kohashi, et al., “Clinical Significance of Signal Regulatory Protein Alpha and T Cell Immunoreceptor With Immunoglobulin and Immunoreceptor Tyrosine-based Inhibition Motif Domain Expression in Undifferentiated Pleomorphic Sarcoma,” Journal of Cancer Research and Clinical Oncology 149, no. 6 (2023): 2425–2436.

[515] M. Umakoshi, Y. Kudo-Asabe, H. Tsuchie, et al., “Prognostic Value of Cancer-Associated Fibroblast Marker Expression in the Intratumoral and Marginal Areas of Soft Tissue Sarcoma,” Pathobiology 92, no. 1 (2025): 1–17.

[516] C. Xu, L. Yan, X. Guan, et al., “Tsp2 Facilitates Tumor-associated Fibroblasts Formation and Promotes Tumor Progression in Retroperitoneal Liposarcoma,” International Journal of Biological Sciences 18, no. 13 (2022): 5038–5055.

[517] C. Bai, S. Li, Z. Tan, and Z. Fan, “Targeting MCM2 Activates Cancer-associated Fibroblasts-Like Phenotype and Affects Chemo-resistance of Liposarcoma Cells Against Doxorubicin,” Anti-Cancer Drugs 35, no. 10 (2024): 883–892.

[518] Y. Nagao, A. Yokoi, K. Yoshida, et al., “Uterine Leiomyosarcoma Cell-derived Extracellular Vesicles Induce the Formation of Cancer-associated Fibroblasts,” Biochimica et Biophysica Acta: Molecular Basis of Disease 1870, no. 4 (2024): 167103.

[519] M. Panagi, F. Mpekris, C. Voutouri, et al., “Stabilizing Tumor-Resident Mast Cells Restores T-Cell Infiltration and Sensitizes Sarcomas to PD-L1 Inhibition,” Clinical Cancer Research 30, no. 11 (2024): 2582–2597.

[520] M. T. Broz, E. Y. Ko, K. Ishaya, et al., “Metabolic Targeting of Cancer Associated Fibroblasts Overcomes T-cell Exclusion and Chemoresistance in Soft-tissue Sarcomas,” Nature Communications 15, no. 1 (2024): 2498.

[521] B. W. Zheng, M. L. Yang, W. Huang, et al., “Prognostic Significance of Tumor-Associated Macrophages in Chondroblastoma and Their Association With Response to Adjuvant Radiotherapy,” Journal of Inflammation Research 14 (2021): 1991–2005.

[522] S. Bissinger, C. Hage, V. Wagner, et al., “Macrophage Depletion Induces Edema Through Release of Matrix-degrading Proteases and Proteoglycan Deposition,” Science Translational Medicine 13, no. 598 (2021): eabd4550.

[523] J. R. Kalden and H. Schulze-Koops, “Immunogenicity and Loss of Response to TNF Inhibitors: Implications for Rheumatoid Arthritis Treatment,” Nature Reviews Rheumatology 13, no. 12 (2017): 707–718.

[524] A. Rubbert-Roth, F. Atzeni, I. F. Masala, R. Caporali, C. Montecucco, and P. Sarzi-Puttini, “TNF Inhibitors in Rheumatoid Arthritis and Spondyloarthritis: Are They the Same?,” Autoimmunity Reviews 17, no. 1 (2018): 24–28.

[525] Y. Tanaka, Y. Miyazaki, M. Kawanishi, H. Yamasaki, and T. Takeuchi, “Long-term Safety and Efficacy of Anti-TNF Multivalent VHH Antibodies ozoralizumab in Patients With Rheumatoid Arthritis,” RMD Open 10, no. 3 (2024): e004480.

[526] J. S. Smolen, E. Feist, S. Fatenejad, et al., “Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis,” New England Journal of Medicine 387, no. 8 (2022): 715–726.

[527] R. Fleischmann, M. C. Genovese, K. Maslova, H. Leher, A. Praestgaard, and G. R. Burmester, “Long-term Safety and Efficacy of sarilumab Over 5 Years in Patients With Rheumatoid Arthritis Refractory to TNF Inhibitors,” Rheumatology 60, no. 11 (2021): 4991–5001.

[528] M. C. Genovese, M. E. Weinblatt, J. A. Aelion, et al., “ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients with Rheumatoid Arthritis with an Inadequate Response to Methotrexate: A Randomized,” Double-Blind Study Arthritis & Rheumatology 70, no. 11 (2018): 1710–1720.

[529] E. Yuba, E. Budina, K. Katsumata, et al., “Suppression of Rheumatoid Arthritis by Enhanced Lymph Node Trafficking of Engineered Interleukin-10 in Murine Models,” Arthritis & Rheumatology 73, no. 5 (2021): 769–778.

[530] T. Takeuchi, Y. Tanaka, S. Soen, et al., “Effects of the Anti-RANKL Antibody Denosumab on Joint Structural Damage in Patients With Rheumatoid Arthritis Treated With Conventional Synthetic Disease-modifying Antirheumatic Drugs (DESIRABLE study): A Randomised, Double-blind, Placebo-controlled Phase 3 Trial,” Annals of the Rheumatic Diseases 78, no. 7 (2019): 899–907.

[531] Y. Chi, Y. Li, Q. Cheng, et al., “Efficacy and Safety of narlumosbart, an Anti-RANKL Monoclonal Antibody, in Postmenopausal Women With Osteoporosis: A Multi-center, Randomized, Double-blind, Placebo- and Active-controlled, Phased II Study,” EClinicalMedicine 85 (2025): 103329.

[532] F. Eckstein, M. C. Hochberg, H. Guehring, et al., “Long-term Structural and Symptomatic Effects of Intra-articular Sprifermin in Patients With Knee Osteoarthritis: 5-year Results From the FORWARD Study,” Annals of the Rheumatic Diseases 80, no. 8 (2021): 1062–1069.

[533] H. A. Blair and E. D. Deeks, “Abatacept: A Review in Rheumatoid Arthritis,” Drugs 77, no. 11 (2017): 1221–1233.

[534] A. Hosseini, T. Gharibi, F. Marofi, Z. Babaloo, and B. Baradaran, “CTLA-4: From Mechanism to Autoimmune Therapy,” International Immunopharmacology 80 (2020): 106221.

[535] A. P. Cope, M. Jasenecova, J. C. Vasconcelos, et al., “Abatacept in Individuals at High Risk of Rheumatoid Arthritis (APIPPRA): A Randomised, Double-blind, Multicentre, Parallel, Placebo-controlled, Phase 2b Clinical Trial,” Lancet 403, no. 10429 (2024): 838–849.

[536] J. Rech, K. Tascilar, M. Hagen, et al., “Abatacept Inhibits Inflammation and Onset of Rheumatoid Arthritis in Individuals at High Risk (ARIAA): A Randomised, International, Multicentre, Double-blind, Placebo-controlled Trial,” Lancet 403, no. 10429 (2024): 850–859.

[537] J. Tuttle, E. Drescher, J. A. Simon-Campos, et al., “A Phase 2 Trial of Peresolimab for Adults With Rheumatoid Arthritis,” New England Journal of Medicine 388, no. 20 (2023): 1853–1862.

[538] Q. Tang, X. Zhang, X. Zhu, et al., “Camrelizumab in Combination With Doxorubicin, Cisplatin, Ifosfamide, and Methotrexate in Neoadjuvant Treatment of Resectable Osteosarcoma: A Prospective, Single-arm, Exploratory Phase II Trial,” Cancer Medicine 13, no. 18 (2024): e70206.

[539] K. Boye, A. Longhi, T. Guren, et al., “Pembrolizumab in Advanced Osteosarcoma: Results of a Single-arm, Open-label, Phase 2 Trial,” Cancer Immunology, Immunotherapy 70, no. 9 (2021): 2617–2624.

[540] D. M. Schwartz, Y. Kanno, A. Villarino, M. Ward, M. Gadina, and J. J. O'Shea, “JAK Inhibition as a Therapeutic Strategy for Immune and Inflammatory Diseases,” Nature Reviews Drug Discovery 16, no. 12 (2017): 843–862.

[541] J. Liu, Y. Jiang, S. Zhang, et al., “Ivarmacitinib, a Selective Janus Kinase 1 Inhibitor, in Patients With Moderate-to-severe Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs: Results From a Phase III Randomised Clinical Trial,” Annals of the Rheumatic Diseases 84, no. 2 (2025): 188–200.

[542] M. F. Robinson, N. Damjanov, B. Stamenkovic, et al., “Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients with Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate,” Arthritis & Rheumatology 72, no. 10 (2020): 1621–1631.

[543] M. C. Genovese, K. Kalunian, J. E. Gottenberg, et al., “Effect of Filgotinib vs Placebo on Clinical Response in Patients with Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial,” Jama 322, no. 4 (2019): 315–325.

[544] Y. Yazici, T. E. McAlindon, A. Gibofsky, et al., “A Phase 2b Randomized Trial of lorecivivint, a Novel Intra-articular CLK2/DYRK1A Inhibitor and Wnt Pathway Modulator for Knee Osteoarthritis,” Osteoarthritis and Cartilage 29, no. 5 (2021): 654–666.

[545] P. D. Miller, J. D. Adachi, B. H. Albergaria, et al., “Efficacy and Safety of Romosozumab among Postmenopausal Women with Osteoporosis and Mild-to-Moderate Chronic Kidney Disease,” Journal of Bone and Mineral Research 37, no. 8 (2022): 1437–1445.

[546] K. G. Saag, J. Petersen, M. L. Brandi, et al., “Romosozumab or Alendronate for Fracture Prevention in Women With Osteoporosis,” New England Journal of Medicine 377, no. 15 (2017): 1417–1427.

[547] E. F. Eriksen, R. W. Boyce, Y. Shi, et al., “Reconstruction of Remodeling Units Reveals Positive Effects After 2 and 12 Months of romosozumab Treatment,” Journal of Bone and Mineral Research 39, no. 6 (2024): 729–736.

[548] W. D. Tap, V. M. Villalobos, G. M. Cote, et al., “Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients with Advanced Chondrosarcoma,” Journal of Clinical Oncology 38, no. 15 (2020): 1693–1701.

[549] D. Fiorentino, A. R. Mangold, V. P. Werth, et al., “Efficacy, Safety, and Target Engagement of dazukibart, an IFNbeta Specific Monoclonal Antibody, in Adults With Dermatomyositis: A Multicentre, Double-blind, Randomised, Placebo-controlled, Phase 2 Trial,” Lancet 405, no. 10473 (2025): 137–146.

[550] Y. Wang, Y. Kong, J. Du, et al., “Injection of human Umbilical Cord Mesenchymal Stem Cells Exosomes for the Treatment of Knee Osteoarthritis: From Preclinical to Clinical Research,” Journal of Translational Medicine 23, no. 1 (2025): 641.

[551] N. Mensali, H. Koksal, S. Joaquina, et al., “ALPL-1 Is a Target for Chimeric Antigen Receptor Therapy in Osteosarcoma,” Nature Communications 14, no. 1 (2023): 3375.

[552] J. H. Chen, C. L. Zhao, J. Zhang, et al., “Enhancing Immunogenicity and Release of in Situ-generated Tumor Vesicles for Autologous Vaccines,” Journal of Control Release 381 (2025): 113614.

[553] J. Pang, L. Huang, Y. Lian, Z. Yuan, F. Wang, and L. M. Zhang, “Co-delivery of siAEG-1 and doxorubicin to Treat Osteosarcoma via Nanomicelles for Azide-alkyne "Click" Conjugation of Poly(l-lysine) Dendrons Onto Zein,” International Journal of Biological Macromolecules 264, no. Pt 2 (2024): 130729.

[554] M. Guo, H. Liu, Y. Yu, et al., “Lactobacillus Rhamnosus GG Ameliorates Osteoporosis in Ovariectomized Rats by Regulating the Th17/Treg Balance and Gut Microbiota Structure,” Gut Microbes 15, no. 1 (2023): 2190304.

[555] N. Aryaeian, M. Hadidi, M. Mahmoudi, M. Asgari, Z. S. Hezaveh, and S. K. Sadehi, “The Effect of Black Barberry Hydroalcoholic Extract on Immune Mediators in Patients With Active Rheumatoid Arthritis: A Randomized, Double-blind, Controlled Clinical Trial,” Phytotherapy Research 35, no. 2 (2021): 1062–1068.

[556] S. Qdaisat, B. Wummer, B. D. Stover, et al., “Sensitization of Tumours to Immunotherapy by Boosting Early Type-I Interferon Responses Enables Epitope Spreading,” Nature Biomedical Engineering 9, no. 9 (2025): 1437–1452.

[557] T. W. Laetsch, K. Ludwig, P. M. Williams, et al., “Phase II Study of Samotolisib in Children and Young Adults with Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D,” JCO Precision Oncology 8 (2024): e2400258.

[558] Y. Chen, Q. W. Chen, F. S. Fu, H. Y. Gu, A. Yu, and X. Z. Zhang, “Bone Destruction-Chemotactic Osteoprogenitor Cells Deliver Liposome Nanomedicines for the Treatment of Osteosarcoma and Osteoporosis,” ACS Nano 18, no. 43 (2024): 29864–29879.

[559] R. J. Miron, N. E. Estrin, A. Sculean, and Y. Zhang, “Understanding Exosomes: Part 2-Emerging Leaders in Regenerative Medicine,” Periodontology 2000 94, no. 1 (2024): 257–414.

[560] G. Bellini, D. Di Pinto, C. Tortora, et al., “The Role of Mifamurtide in Chemotherapy-induced Osteoporosis of Children With Osteosarcoma,” Current Cancer Drug Targets 17, no. 7 (2017): 650–656.

[561] U. M. Pirker-Fruhauf, J. Friesenbichler, E. C. Urban, B. Obermayer-Pietsch, and A. Leithner, “Osteoporosis in Children and Young Adults: A Late Effect After Chemotherapy for Bone Sarcoma,” Clinical Orthopaedics and Related Research 470, no. 10 (2012): 2874–2885.

[562] Y. U. Chen, S. F. Xu, M. Xu, and X. C. Yu, “Postoperative Infection and Survival in Osteosarcoma Patients: Reconsideration of Immunotherapy for Osteosarcoma,” Molecular and Clinical Oncology 3, no. 3 (2015): 495–500.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.